A publication issued at stated, more or less regular, intervals.
Publications in any medium issued in successive parts bearing numerical or chronological designations and intended to be continued indefinitely. (ALA Glossary of Library and Information Science, 1983, p203)
The transference of a part of or an entire liver from one human or animal to another.
Preservation of cells, tissues, organs, or embryos by freezing. In histological preparations, cryopreservation or cryofixation is used to maintain the existing form, structure, and chemical composition of all the constituent elements of the specimens.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
Infections resulting from the implantation of prosthetic devices. The infections may be acquired from intraoperative contamination (early) or hematogenously acquired from other sites (late).
Flaps of tissue that prevent regurgitation of BLOOD from the HEART VENTRICLES to the HEART ATRIA or from the PULMONARY ARTERIES or AORTA to the ventricles.
An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient.
The vessels carrying blood away from the heart.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.
The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
Agents that destroy bone marrow activity. They are used to prepare patients for BONE MARROW TRANSPLANTATION or STEM CELL TRANSPLANTATION.
A heterogenous group of disorders characterized by alterations of mitochondrial metabolism that result in muscle and nervous system dysfunction. These are often multisystemic and vary considerably in age at onset (usually in the first or second decade of life), distribution of affected muscles, severity, and course. (From Adams et al., Principles of Neurology, 6th ed, pp984-5)
A type of ILEUS, a functional not mechanical obstruction of the INTESTINES. This syndrome is caused by a large number of disorders involving the smooth muscles (MUSCLE, SMOOTH) or the NERVOUS SYSTEM.
An enzyme that catalyzes the transfer of 2-deoxy-D-ribose from THYMIDINE to orthophosphate, thereby liberating thymidine.
2'-Deoxyuridine. An antimetabolite that is converted to deoxyuridine triphosphate during DNA synthesis. Laboratory suppression of deoxyuridine is used to diagnose megaloblastic anemias due to vitamin B12 and folate deficiencies.
Diseases in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.
A medical specialty primarily concerned with prevention of disease (PRIMARY PREVENTION) and the promotion and preservation of health in the individual.
Progenitor cells from which all blood cells derive.
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
A verocytotoxin-producing serogroup belonging to the O subfamily of Escherichia coli which has been shown to cause severe food-borne disease. A strain from this serogroup, serotype H7, which produces SHIGA TOXINS, has been linked to human disease outbreaks resulting from contamination of foods by E. coli O157 from bovine origin.
A peptide hormone that lowers calcium concentration in the blood. In humans, it is released by thyroid cells and acts to decrease the formation and absorptive activity of osteoclasts. Its role in regulating plasma calcium is much greater in children and in certain diseases than in normal adults.
An enzyme that transfers methyl groups from O(6)-methylguanine, and other methylated moieties of DNA, to a cysteine residue in itself, thus repairing alkylated DNA in a single-step reaction. EC 2.1.1.63.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
The rate at which oxygen is used by a tissue; microliters of oxygen STPD used per milligram of tissue per hour; the rate at which oxygen enters the blood from alveolar gas, equal in the steady state to the consumption of oxygen by tissue metabolism throughout the body. (Stedman, 25th ed, p346)
A plant genus of the family ANNONACEAE. It has edible fruit and seeds which contain acetogenins and benzoquinazoline and other alkaloids.
Body of knowledge related to the use of organisms, cells or cell-derived constituents for the purpose of developing products which are technically, scientifically and clinically useful. Alteration of biologic function at the molecular level (i.e., GENETIC ENGINEERING) is a central focus; laboratory methods used include TRANSFECTION and CLONING technologies, sequence and structure analysis algorithms, computer databases, and gene and protein structure function analysis and prediction.
Places for cultivation and harvesting of fish, particularly in sea waters. (from McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
The transference of a kidney from one human or animal to another.
Hospitals which provide care for the military personnel and usually for their dependents.
Copies of a work or document distributed to the public by sale, rental, lease, or lending. (From ALA Glossary of Library and Information Science, 1983, p181)
Cyclopentanophenanthrenes with a 6-membered lactone ring attached at the 17-position and SUGARS attached at the 3-position. They are found in BUFONIDAE and often possess cardiotonic properties.
Venoms produced by frogs, toads, salamanders, etc. The venom glands are usually on the skin of the back and contain cardiotoxic glycosides, cholinolytics, and a number of other bioactive materials, many of which have been characterized. The venoms have been used as arrow poisons and include bufogenin, bufotoxin, bufagin, bufotalin, histrionicotoxins, and pumiliotoxin.
Time period from 1901 through 2000 of the common era.
The branch of psychology which seeks to learn more about the fundamental causes of behavior by studying various psychologic phenomena in controlled experimental situations.
The facilitation of a chemical reaction by material (catalyst) that is not consumed by the reaction.
A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.
An increase in the total red cell mass of the blood. (Dorland, 27th ed)
A clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets.
A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS.

Natural history of papillary lesions of the urinary bladder in schistosomiasis. (1/9074)

Variable epithelial hyperplasia was observed in urinary bladder of nine capuchin monkeys (Cebus apella) when examined at cystotomy 94 to 164 weeks after infection with Schistosoma haematobium. These hosts were followed for 24 to 136 weeks postcystotomy to determine the status of bladder lesions in relation to duration of infection and to ascertain whether lesion samples removed at cystotomy reestablished themselves in autologous and heterologous transfers. There was involution of urothelial hyperplasia in eight of nine animals and no evidence for establishment of transplanted bladder lesions.  (+info)

Donor MHC and adhesion molecules in transplant arteriosclerosis. (2/9074)

Transplant-associated arteriosclerosis remains an obstacle to long-term graft survival. To determine the contribution to transplant arteriosclerosis of MHC and adhesion molecules from cells of the donor vasculature, we allografted carotid artery loops from six mutant mouse strains into immunocompetent CBA/CaJ recipients. The donor mice were deficient in either MHC I molecules or MHC II molecules, both MHC I and MHC II molecules, the adhesion molecule P-selectin, intercellular adhesion molecule (ICAM)-1, or both P-selectin and ICAM-1. Donor arteries in which ICAM-1, MHC II, or both MHC I and MHC II were absent showed reductions in neointima formation of 52%, 33%, and 38%, respectively, due primarily to a reduction in smooth muscle cell (SMC) accumulation. In P-selectin-deficient donor arteries, neointima formation did not differ from that in controls. In donor arteries lacking both P-selectin and ICAM-1, the size of the neointima was similar to that in those lacking ICAM-1 alone. In contrast, neointima formation increased by 52% in MHC I-deficient donor arteries. The number of CD4-positive T cells increased by 2.8-fold in MHC I-deficient arteries, and that of alpha-actin-positive SMCs by twofold. These observations indicate that ICAM-1 and MHC II molecules expressed in the donor vessel wall may promote transplant-associated arteriosclerosis. MHC I molecules expressed in the donor may have a protective effect.  (+info)

Organ-selective homing defines engraftment kinetics of murine hematopoietic stem cells and is compromised by Ex vivo expansion. (3/9074)

Hematopoietic reconstitution of ablated recipients requires that intravenously (IV) transplanted stem and progenitor cells "home" to organs that support their proliferation and differentiation. To examine the possible relationship between homing properties and subsequent engraftment potential, murine bone marrow (BM) cells were labeled with fluorescent PKH26 dye and injected into lethally irradiated hosts. PKH26(+) cells homing to marrow or spleen were then isolated by fluorescence-activated cell sorting and assayed for in vitro colony-forming cells (CFCs). Progenitors accumulated rapidly in the spleen, but declined to only 6% of input numbers after 24 hours. Although egress from this organ was accompanied by a simultaneous accumulation of CFCs in the BM (plateauing at 6% to 8% of input after 3 hours), spleen cells remained enriched in donor CFCs compared with marrow during this time. To determine whether this differential homing of clonogenic cells to the marrow and spleen influenced their contribution to short-term or long-term hematopoiesis in vivo, PKH26(+) cells were sorted from each organ 3 hours after transplantation and injected into lethally irradiated Ly-5 congenic mice. Cells that had homed initially to the spleen regenerated circulating leukocytes (20% of normal counts) approximately 2 weeks faster than cells that had homed to the marrow, or PKH26-labeled cells that had not been selected by a prior homing step. Both primary (17 weeks) and secondary (10 weeks) recipients of "spleen-homed" cells also contained approximately 50% higher numbers of CFCs per femur than recipients of "BM-homed" cells. To examine whether progenitor homing was altered upon ex vivo expansion, highly enriched Sca-1(+)c-kit+Lin- cells were cultured for 9 days in serum-free medium containing interleukin (IL)-6, IL-11, granulocyte colony-stimulating factor, stem cell factor, flk-2/flt3 ligand, and thrombopoietin. Expanded cells were then stained with PKH26 and assayed as above. Strikingly, CFCs generated in vitro exhibited a 10-fold reduction in homing capacity compared with fresh progenitors. These studies demonstrate that clonogenic cells with differential homing properties contribute variably to early and late hematopoiesis in vivo. The dramatic decline in the homing capacity of progenitors generated in vitro underscores critical qualitative changes that may compromise their biologic function and potential clinical utility, despite their efficient numerical expansion.  (+info)

Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. (4/9074)

The immunomodulatory effect of allogeneic blood transfusions (ABT) has been known for many years. However, a complete understanding of the effects of ABT on the recipient's immune system has remained elusive. Soluble HLA class I (sHLA-I), HLA class II (sHLA-II), and Fas ligand (sFasL) molecules may play immunoregulatory roles. We determined by double-determinant immunoenzymatic assay (DDIA) sHLA-I, sHLA-II, and sFasL concentrations in different blood components. sHLA-I and sFasL levels in red blood cells (RBCs) stored for up to 30 days and in random-donor platelets are significantly (P <.001) higher than in other blood components and their amount is proportionate to the number of residual donor leukocytes and to the length of storage. Blood components with high sHLA-I and sFasL levels play immunoregulatory roles in vitro as in allogeneic mixed lymphocyte responses (MLR) and antigen-specific cytotoxic T-cell (CTL) activity, and induce apoptosis in Fas-positive cells. These data suggest that soluble molecules in blood components are functional. If these results are paralleled in vivo, they should be taken into account in transfusion practice. Blood components that can cause immunosuppression should be chosen to induce transplantation tolerance, whereas blood components that lack immunosuppressive effects should be preferred to reduce the risk of postoperative complications and cancer recurrence.  (+info)

Bone marrow transplantation in pediatric patients with therapy-related myelodysplasia and leukemia. (5/9074)

Eleven children underwent BMT for therapy-related MDS or leukemia, four from HLA-identical siblings and seven from unrelated donors. Ten of the 11 were conditioned with busulfan and cyclophosphamide as the majority had received prior irradiation to the chest and/or abdomen. All patients engrafted. Regimen-related toxicity was more common when compared to historical controls. Eight patients developed acute GVHD and four of eight who survived 100 days post transplant developed extensive chronic GVHD. Non-relapse related mortality occurred in three patients. Five patients developed recurrent malignancy: one died from recurrence of osteosarcoma, three died of recurrent leukemia or MDS and another developed two subsequent malignancies (duodenal carcinoma and anaplastic astrocytoma). Three survive disease-free at 14+, 22+ and 43+ months for a 2 year actuarial cancer-free survival of 24% (95% confidence interval = 5-53%). Although allogeneic BMT can be curative, regimen-related toxicity is frequent and recurrent malignancy remains the major obstacle.  (+info)

Risk factors for severe hemorrhagic cystitis following BMT. (6/9074)

Hemorrhagic cystitis (HC) is a common toxicity of preparative regimens for bone marrow transplantation (BMT). Severe HC often requires prolonged and expensive hospitalization, and occasionally can result in death. To investigate the risk factors for severe HC, we conducted a retrospective study among 1908 patients who received BMTs at the University of Minnesota during 1974 to 1993. A previous report from our institution reported on 977 of these patients. We identified all patients with genitourinary complication within 100 days post-BMT from the BMT database. Medical charts for these patients were reviewed to determine whether the patient had HC and also the grade of HC. A total of 208 HC cases were identified during the study period. Of them, 92 patients had severe HC, an incidence of 5% (95% CI = 4-6%). We found that grade II-IV graft-versus-host disease (RR = 2.56; 95% CI = 1.43-4.56), use of busulfan (RR = 2.69; 95% CI = 1.35-5.35), and age at transplant (RR = 2.20; 95% CI = 1.27-3.81, for age of 10-30 compared to age of 0-9) were related to an increased risk of HC. In contrast, transplant year was inversely associated with the risk of HC (trend test, P < 0.01). We did not find any significant difference in HC with the use of prophylactic Mesna.  (+info)

The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation. (7/9074)

At our institution, the cytomegalovirus (CMV) prophylaxis protocol for allogeneic bone marrow transplant (BMT) recipients who are CMV-seropositive or receive marrow from a CMV-seropositive donor consists of a surveillance bronchoscopy approximately 35 days posttransplant. Patients with a positive surveillance bronchoscopy for CMV receive pre-emptive ganciclovir. In order to determine the utility of other screening methods for CMV, we prospectively performed weekly CMV antigenemia, and blood, urine and throat cultures from time of engraftment to day 120 post-BMT in 126 consecutive patients. Pre-emptive ganciclovir was given to 11/81 patients (13.6%) because of a positive surveillance bronchoscopy for CMV. Results of CMV blood, urine and throat cultures and the antigenemia assay done prior to or at the time of the surveillance bronchoscopy were analyzed for their ability to predict the bronchoscopy result. The antigenemia test had the highest positive and negative predictive values (72% and 96%, respectively). The ability of these tests to predict CMV disease was evaluated in the 70 patients with a negative surveillance bronchoscopy who did not receive pre-emptive ganciclovir. Of 19 cases of active CMV disease, CMV antigenemia was positive in 15 patients (79%) a mean of 34 days preceding symptoms. Blood cultures were positive in 14/19 patients (74%) a mean of 31 days before onset of disease. CMV antigenemia is useful for predicting the surveillance bronchoscopy result, and also predicts the development of CMV disease in the majority of patients missed by the surveillance bronchoscopy.  (+info)

Disappearance of lupus anticoagulant after allogeneic bone marrow transplantation. (8/9074)

Lupus anticoagulant antibodies have never been reported to disappear after either allogeneic or autologous bone marrow transplantation in humans. We report the first case of disappearance of lupus anticoagulant antibodies in a patient without systemic lupus erythematosus or clinical evidence of other autoimmune disorders, who received an allogeneic bone marrow transplant as treatment for chronic myeloid leukemia. Although marrow transplantation is not a recognized therapy for antiphospholipid syndrome, our observation should be considered another example of the capability of intensive chemo-radiotherapy followed by stem cell transplantation to ablate a pathologic marrow clone resulting in an autoimmune disorder and improve, or even cure, some severe autoimmune diseases.  (+info)

Bone marrow transplantation, 2016; doi:10.1038/bmt.2016.123. Authors: Green D J, Bensinger W I, Holmberg L A, Gooley T, Till B G Green D J, Bensinger W I, Holmberg L A, Gooley T, Till B G, Budde L E, Pagel J M, Frayo S L, Roden J E, Hedin L, Press O W, Gopal A K et al.(7) Affiliation: Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; City of Hope National Medical Center, Duarte, CA, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; ...
Hotels near Fred Hutchinson Cancer Research Center, Seattle on TripAdvisor: Find 111,494 traveller reviews, 50,608 candid photos, and prices for 276 hotels near Fred Hutchinson Cancer Research Center in Seattle, WA.
Cytomegalovirus (CMV) infection causes significant morbidity and mortality in the setting of immunodeficiency, including the immune reconstitution phase following allogeneic stem cell transplantation (SCT). We assessed CMV-specific CD4(+) and CD8(+) T-cell responses in 87 HLA-A*0201-positive (A2+) and/or B*0702-positive (B7+) allogeneic stem cell transplant recipients using HLA-peptide tetramer staining and cytokine flow cytometry (CFC) to examine the association of CMV-specific immune reconstitution and CMV antigenemia following SCT. Strong CMV-specific T-cell responses recovered in most subjects (77 of 87, 88%) after SCT. Frequencies of CMV-specific CD8(+) T cells were significantly higher in those subjects who experienced early antigenemia relative to those who did not (2.2% vs 0.33%, P =.0002), as were frequencies of CMV-specific CD4(+) T cells (1.71% vs 0.75%, P =.002). Frequencies of CMV-specific CD8(+) T cells were also higher in subjects experiencing late antigenemia (2.4% vs 0.57%). When we
One of the worlds leading bone marrow transplant experts is recommending a significant change to current transplant practice for patients who need marrow or adult stem cells from an unrelated donor to treat hematologic malignancies. Fred Appelbaum, M.D., director of the Clinical Research Division at Fred Hutchinson Cancer Research Center, asserts that bone marrow - not circulating, peripheral blood, which is the current norm - should be the source for unrelated donor adult stem cells for most patients who require a transplant. The reason: because there is less incidence of chronic graft-versus-host disease (GVHD), which can be a debilitating side effect of transplantation.
Pediatric anaplastic large cell lymphoma (ALCL) is a chemosensitive malignancy, but about 30% of patients experience relapse. In most of these patients, a second complete remission is obtainable with salvage chemotherapy, though relapse free survival rates are as low as 30-60%. Herein, we report a 6-year-old boy with relapsed anaplastic lymphoma kinase (ALK) positive ALCL successfully treated with vinblastine monotherapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT), with a reduced intensity conditioning (RIC) regimen, from his father. One HLA locus from the father was mismatched. The boy had neither severe graft-versus-host disease nor transplantation related complications. He is currently well and has remained disease free for 10 months, to date, since transplantation. Allo-HSCT with a RIC regimen may be a promising treatment strategy for relapsed ALK positive ALCL based on obtaining graft-versus lymphoma effects as well as reducing transplantation-related mortality.
Researchers at Fred Hutchinson Cancer Research Center have developed biodegradable nanoparticles that can be used to genetically program immune cells to recognize and destroy cancer cells - while the immune cells are still inside the body.. In a proof-of-principle study to be published April 17 [2017] in Nature Nanotechnology, the team showed that nanoparticle-programmed immune cells, known as T cells, can rapidly clear or slow the progression of leukemia in a mouse model.. Our technology is the first that we know of to quickly program tumor-recognizing capabilities into T cells without extracting them for laboratory manipulation, said Fred Hutchs Dr. Matthias Stephan, the studys senior author. The reprogrammed cells begin to work within 24 to 48 hours and continue to produce these receptors for weeks. This suggests that our technology has the potential to allow the immune system to quickly mount a strong enough response to destroy cancerous cells before the disease becomes ...
The Avgousti lab at the Fred Hutchinson Cancer Research Center has an opening for a postdoctoral fellow. Our laboratory uses a multidisciplinary approach to investigate the mechanisms by which viruses hijack chromatin. Due to the major advancement in sequencing technologies and the expansion of the field of epigenetics, exploiting viruses to investigate chromatin biology has enormous potential. Our goal is to advance basic understanding of viral manipulation of chromatin and uncover new aspects of chromatin biology.. Much like the cellular genome, viral genomes are compacted in virus particles with small basic molecules to maximize space and be poised for gene expression. Some DNA viruses use cellular histone proteins to compact their genomes whereas others use small basic molecules. Adenoviruses encode their own histone-like protein, called protein VII, that forms a beads on a string assembly with the viral genome. By examining protein VII in host chromatin, we discovered that protein VII ...
Fred Hutchinson Cancer Research Center is launching a new integrated research center to prevent and find cures for cancers caused by infectious agents. It
Market your lab products and lab equipment to the life science professionals at the Fred Hutchinson Cancer Research Center in Seattle, WA in the upcoming BioResearch Product Faire™ Event.
Reduced intensity conditioning (RIC) regimens have allowed older patients and those with comorbidities to receive hematopoietic cell transplantation (HCT). We analyzed medical costs from the beginning of conditioning to 100 days after HCT for 484 patients and up to 2 years for 311 patients who underwent a RIC HCT at two institutions from January 2008 to December 2010. Multiple linear regression was used to analyze the association between clinical variables, center effect, and costs. Patient and transplant characteristics were comparable between the sites, although differences were seen in pretransplant performance scores. Significant predictors for lower costs for the first 100 days included a diagnosis of lymphoma/myeloma and use of human leukocyte antigen-matched related donors. Grade II-IV acute graft-versus-host disease (GVHD) was associated with higher costs. The overall short-term costs between the two institutions were comparable when adjusted for clinical variables (p = .43). Late costs ...
Storb R, Gyurkocza B, Storer BE, Maloney DG, Sorror ML, Mielcarek M, Martin PJ, Sandmaier BM. 2013. Allogeneic Hematopoietic Cell Transplantation Following Minimal Intensity Conditioning: Predicting Acute Graft-versus-Host Disease and Graft-versus-Tumor Effects.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 19(5):792-8. Abstract ...
Hill, GR, Ferrara, JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. vol. 95. 2000. pp. 2754-9. (Highlights the importance of the gastrointestinal tract in the pathogenesis of GVHD). Przepiorka, D, Weisdorf, D, Martin, P. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. vol. 15. 1995. pp. 825-8. (Key article on grading of acute GVHD). Cahn, JY, Klein, JP, Lee, SJ. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood. vol. 106. 2005. pp. 1495-1500. (Key article on grading of acute GVHD). Eapen, M, Horowitz, MM, Klein, JP. Higher mortality after allogeneic peripheral-blood transplantation compared with bone ...
Bone marrow transplantation, or allogeneic hematopoietic stem cell transplant (HCT), is the only curative therapy for many patients with leukemia. Certain immune cells, called T cells, contained in the donor HCT graft can cause a graft versus leukemia (GVL) effect which eliminates leukemic cells. Unfortunately, there are also donor T cells in the HCT graft that can cause a condition called graft versus host disease (GVHD). GVHD is a life-threatening immune response that remains the major barrier to the success of transplantation. Dr. ...
The purpose of the study is to examine the safety and effectiveness of a reduced intensity conditioning regimen and allogeneic bone marrow transplant for people with systemic sclerosis. In an allogeneic bone marrow transplant procedure, bone marrow is taken from a healthy donor and transplanted into the patient. Bone marrow can be donated by a family member or an unrelated donor who is a complete tissue type match.. Participants will receive the chemotherapy and low dose radiation conditioning regimen consisting of the following: Fludarabine will be given intravenously for 5 days. Cyclophosphamide will be given intravenously on the first and second day. After completing the fludarabine and cyclophosphamide, patients will receive a single low dose of total body irradiation. The next day, patients will receive the allogeneic bone marrow transplant. On the third and fourth day after the transplant, patients will receive high dose intravenous cyclophosphamide. This is given to help prevent two ...
The purpose of the study is to examine the safety and effectiveness of a reduced intensity conditioning regimen and allogeneic bone marrow transplant for people with systemic sclerosis. In an allogeneic bone marrow transplant procedure, bone marrow is taken from a healthy donor and transplanted into the patient. Bone marrow can be donated by a family member or an unrelated donor who is a complete tissue type match.. Participants will receive the chemotherapy and low dose radiation conditioning regimen consisting of the following: Fludarabine will be given intravenously for 5 days. Cyclophosphamide will be given intravenously on the first and second day. After completing the fludarabine and cyclophosphamide, patients will receive a single low dose of total body irradiation. The next day, patients will receive the allogeneic bone marrow transplant. On the third and fourth day after the transplant, patients will receive high dose intravenous cyclophosphamide. This is given to help prevent two ...
平成23年4月 岡山大学病院講師(輸血部). 【一言】丁寧で安定感のある診療を心がけています。. 【研究テーマ】移植後肺合併症、ドナーリンパ球輸注によるGVL効果. 【主な業績】. ● Nishie M , Fujii N, Mimura Y , Asano T, Mimura-Kimura Y, Aoe K, Aoe M, Nakashima H, Fujiwara H, Nishimori H, Matsuoka KI, Kondo E, Maeda Y, Tanimoto M. Vigorous inflammatory responses in non-infectious pulmonary complication induced by donor lymphocyte infusion. Transfusion. 2015 (in press). ● Asano T, Fujii N, Niiya D, Nishimori H, Fujii K, Matsuoka K, Ichimura K, Hamada T, Kondo E, Maeda Y, Tanimoto Y, Shinagawa K, Tanimoto M. Complete resolution of steroid-resistant organizing pneumonia associated with myelodysplastic syndrome following allogeneic hematopoietic cell transplantation. Springerplus. 2014 Jan 2;3:3. ● Fujii N, Nakase K, Asakura S, Matsuo K, Nawa Y, Sunami K, Nishimori H, Matsuoka K, Kondo E, Maeda Y, Shinagawa K, Hara M, Tanimoto M ...
HOPA supports pharmacy practitioners and seeks to promote and advance hematology/oncology pharmacy to optimize the care of individuals affected by cancer
Mice given short courses of anti-CD4 and anti-CD8 monoclonal antibodies became tolerant of allogeneic skin grafted at the same time. Tolerance could be obtained without T cell depletion across multiple minor antigen mismatches, both in naive and primed animals, demonstrating that peripheral T cells could be tolerized, even if they had been previously activated. Where donor and recipient were incompatible across the whole major histocompatibility complex, specific tolerance could be achieved by using a combination of depleting followed by non-depleting antibodies, where each alone was unsuccessful. Although mice clearly tolerated their original skin grafts, we observed in some strain combinations that a second fresh, but genotypically identical graft, was slowly rejected. Such mice also possessed T cells which could proliferate to donor-type stimulator cells in vitro. Whatever the mechanisms, we have demonstrated that operational transplantation tolerance can be achieved with simple, non-toxic antibody
Graft-versus-host disease remains a major cause of transplant-related mortality. Interleukin-2 plus sirolimus synergistically reduces acute graft-versus-host disease in rodents and promotes regulatory T-cells. This phase II trial tested the hypothesis that interleukin-2 would facilitate STAT5 phosphorylation in donor T-cells, expand regulatory T-cells, and ameliorate graft-versus-host disease. Between 4/16/2014-12/19/2015, 20 patients received interleukin-2 (200,000IU/m2 thrice weekly, days 0 to +90) with sirolimus (5-14ng/ml) and tacrolimus (3-7ng/ml) after HLA-matched related or unrelated allogeneic hematopoietic cell transplantation. The study was designed to capture an increase in regulatory T-cells from 16.0% to ,23.2% at day +30. Interleukin-2/sirolimus/tacrolimus significantly increased regulatory T-cells at day +30 compared to our published data with sirolimus/tacrolimus (23.8% versus 16.0%, P=0.0016; 0.052 k/ul versus 0.037 k/ul, P=0.0163), achieving the primary study endpoint. However, ...
H.Joachim Deeg from Fred Hutchinson Cancer Research CenterClinical ResearchFull Member is a speaker at Eurocancersummit-2015 conference | Conferenceseries Ltd
TY - JOUR. T1 - Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma. T2 - A CIBMTR analysis. AU - Epperla, Narendranath. AU - Ahn, Kwang W.. AU - Litovich, Carlos. AU - Ahmed, Sairah. AU - Battiwalla, Minoo. AU - Cohen, Jonathon B.. AU - Dahi, Parastoo. AU - Farhadfar, Nosha. AU - Farooq, Umar. AU - Freytes, Cesar O.. AU - Ghosh, Nilanjan. AU - Haverkos, Bradley. AU - Herrera, Alex. AU - Hertzberg, Mark. AU - Hildebrandt, Gerhard. AU - Inwards, David. AU - Kharfan-Dabaja, Mohamed A.. AU - Khimani, Farhad. AU - Lazarus, Hillard. AU - Lazaryan, Aleksandr. AU - Lekakis, Lazaros. AU - Murthy, Hemant. AU - Nathan, Sunita. AU - Nishihori, Taiga. AU - Pawarode, Attaphol. AU - Prestidge, Tim. AU - Ramakrishnan, Praveen. AU - Rezvani, Andrew R.. AU - Romee, Rizwan. AU - Shah, Nirav N.. AU - Sureda, Ana. AU - Fenske, Timothy S.. AU - Hamadani, Mehdi. PY - 2019/1/10. Y1 - ...
SEATTLE - Study demonstrates that marrow transplantation using HLA-matched unrelated donors can be safe and effective therapy for patients with chronic myeloid leukemia (CML) in chronic phase. Seattle researchers also believe that transplantation should not be limited to younger people, under the age of 40 years. Fred Hutchinson Cancer Research Center researchers published the results of their study in the April 2, 1998, issue of The New England Journal of Medicine.. Transplantation has been shown to be the cure for many blood disorders and inherited diseases, including CML. One obstacle has always been the identification of a suitably matched donor. Previously, it was believed that only those CML patients with an HLA-matched sibling donor had an option for curative treatment. This study concludes that marrow transplantation from an HLA-matched unrelated donor can be the treatment of choice for many CML patients and should be considered early in the course of disease to optimize ...
TY - JOUR. T1 - Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia. T2 - Results of a prospective observational study. AU - Schetelig, Johannes. AU - Hoek, Jennifer. AU - Stilgenbauer, Stephan. AU - Middeke, Jan Moritz. AU - Andersen, Niels Smedegaard. AU - Fox, Christopher P.. AU - Lenhoff, Stig. AU - Volin, Liisa. AU - Shimoni, Avichai. AU - Schroyens, Wilfried. AU - van Gelder, Michel. AU - Bunjes, Donald. AU - van Biezen, Anja. AU - Baldauf, Henning. AU - de Wreede, Liesbeth C.. AU - Tournilhac, Olivier. AU - Kroeger, Nicolaus. AU - Yakoub-Agha, Ibrahim. AU - Dreger, Peter. PY - 2020/8/16. Y1 - 2020/8/16. KW - FOLLOW-UP. KW - RETROSPECTIVE ANALYSIS. KW - EUROPEAN-SOCIETY. KW - CLL. KW - BLOOD. U2 - 10.1038/s41409-020-01013-y. DO - 10.1038/s41409-020-01013-y. M3 - Letter. JO - Bone Marrow Transplantation. JF - Bone Marrow Transplantation. SN - 0268-3369. ER - ...
Fred Hutchs Business Development and Industry Relations manages and commercializes our intellectual property assets. Partners are vital to the commercialization process; our goal is to work as efficiently and collaboratively as possible to achieve shared goals.
Bart L. Scott, MD, MS, is Assistant Professor at the University of Washington Medical Center and Assistant Member at the Fred Hutchinson Cancer Research Center in Seattle, Washington. He received his medical degree from the University of South Alabama and his masters of Science in Epidemiology from the University of Washington, Seattle. He completed his residency in Internal Medicine at Johns Hopkins Hospital in Baltimore, MD, where he also served as Assistant Chief of Services. His medical oncology fellowship was completed at Fred Hutchinson Cancer Research Center. Dr.
Blood, 1996; 88 (9) doi:. Authors: Nash R A, Piñeiro L A, Storb R, Deeg H J, Fitzsimmons W E Nash R A, Piñeiro L A, Storb R, Deeg H J, Fitzsimmons W E, Furlong T, Hansen J A, Gooley T, Maher R M, Martin P, McSweeney P A, Sullivan K M, Anasetti C, Fay J W et al.(9) Affiliation: Fred Hutchinson Cancer Research Center, United States Sample size: 25 Abstract: The safety and potential efficacy of FK506 in combination with a short course of methotrexate (MTX) for the prevention of acute graft-versus-host disease (GVHD) after marrow transplantation from HLA-matched unrelated donors was evaluated in a single-arm Phase II study conducted at two centers. Forty-three patients, 15 to 54 (median 41) years of age, were transplanted for hematologic malignancies. Thirty-seven of 43 evaluable patients had evidence of sustained marrow engraftment. Five patients died before day 17 after transplantation. The median time to an absolute neutrophil count of > 0.5 x 10(5)/L was 21 (range, 14 to 30) days. ...
Non-competitive 5K and one mile run/walk in support of research and awareness for multiple myeloma the second most common type of blood cancer.
Julie R. Park, MD, is attending physician at Seattle Childrens Hospital, professor in pediatrics at the University of Washington School of Medicine and associate in the Clinical Research Division at Fred Hutchinson Cancer Research Center (FHCRC). She is director of the pediatric hematology-oncology fellowship at the University of Washington.. Julie R. Park, MD, is attending physician at Seattle Childrens Hospital, professor in pediatrics at the University of Washington School of Medicine and associate in the Clinical Research Division at Fred Hutchinson Cancer Research Center (FHCRC). She is medical director of Immunotherapy Coordinating Center within the Immunotherapy Integration Hub and is medical director of the Cancer and Blood Disorders Advanced Therapeutics clinical research program.. Dr. Parks primary research focus has been investigating novel therapies for the treatment of refractory and recurrent cancers with a specific focus on high-risk neuroblastoma, a rare but aggressive form of ...
TY - JOUR. T1 - Epstein-barr-virus-related malignant b cell lymphoplasmacytic lymphoma following allogeneic bone marrow transplantation for aplastic anemia. AU - Forman, Stephen J.. AU - Sullivan, John L.. AU - Wright, Christine. AU - Ratech, Howard. AU - Racklin, Barbara. AU - Blume, Karl G.. PY - 1987. Y1 - 1987. N2 - The development of B cell lymphoma has been reported to occur in recipients of a variety of organ transplants, including some patients who have received an allogeneic bone marrow graft. In this report, we describe a patient with severe aplastic anemia who developed a malignant B cell lymphoplasmacytoid proliferation 48 days after undergoing allogeneic marrow transplantation from her HLA-matched MLC-nonreactive brother. Immunologic studies showed this malignancy to be a mixed polyclonal and monoclonal proliferation in donor ceils. Virologie studies documented Epstein Bare infection of the cells. A review of the literature suggests that graft-versus-host disease and treatment of ...
A 60-year-old man presented with impaired consciousness and psychomotor agitation after a second allogeneic haematopoietic stem cell transplantation (HSCT) from a matched unrelated donor for acute myeloid leukaemia. Clinical, biological and radiological evidence suggested a diagnosis of central nervous system graft-versus-host disease (CNS-GvHD). After intrathecal infusion of methylprednisolone, the clinical symptoms as well as the radiological abnormalities disappeared. The present report illustrates the difficulties in the diagnosis and the management of CNS-GvHD, a very rare and still challenging neurological complication that can occur after allogeneic HSCT. ...
PubMedID: 23505556 | Ceruloplasmin is a potential biomarker for aGvHD following allogeneic hematopoietic stem cell transplantation. | PloS one | 1/1/2013
TY - JOUR. T1 - Effect of graft sources on allogeneic hematopoietic stem cell transplantation outcome in adults with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. T2 - a Japanese Society of Hematopoietic Cell Transplantation retrospective analysis. AU - Ohashi, Kazuteru. AU - Nagamura-Inoue, Tokiko. AU - Nagamura, Fumitaka. AU - Tojo, Arinobu. AU - Miyamura, Kouichi. AU - Mori, Takehiko. AU - Kurokawa, Mineo. AU - Taniguchi, Shuichi. AU - Ishikawa, Jun. AU - Morishima, Yasuo. AU - Atsuta, Yoshiko. AU - Sakamaki, Hisashi. PY - 2014/9/1. Y1 - 2014/9/1. N2 - We retrospectively compared transplant outcomes for related bone marrow transplantation (rBMT), related peripheral blood stem cell transplantation (rPBSCT), unrelated bone marrow transplantation (uBMT), and unrelated cord blood transplantation (CBT) in 1,062 patients with chronic myeloid leukemia (CML) aged 20 years or over between January 1, 2000 and December 31, 2009 in Japan. The disease status was as follows: chronic ...
TY - JOUR. T1 - Recipient and donor JAK2 46/1 haplotypes are associated with acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. AU - Balassa, Katalin. AU - Krahling, Tunde. AU - Remenyi, Peter. AU - Batai, Arpad. AU - Bors, Andras. AU - Kiss, Katalin Piroska. AU - Torbagyi, Eva. AU - Gopcsa, Laszlo. AU - Lengyel, Lilla. AU - Barta, Aniko. AU - Varga, Gergely. AU - Tordai, A.. AU - Masszi, T.. AU - Andrikovics, H.. PY - 2016/7/7. Y1 - 2016/7/7. N2 - Several genetic polymorphisms have been implicated to affect the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT). The role of cytokines in acute graft-versus-host disease (aGvHD) is well established and many of the involved cytokines signal through the Janus kinase (JAK) pathways. In this study, we assessed the association of recipient and donor JAK2 46/1 haplotypes and allo-HSCT outcome in a cohort of 124 acute myeloid leukemia patients. Both, recipient and donor 46/1 haplotypes ...
BACKGROUND & OBJECTIVE: Patients with refractory or relapsed acute leukemia after allogeneic hematopoietic stem cell transplantation had a poor prognosis with high death rate due to relapse or transplant-related mortality (TRM). The purpose of this paper was to clarify the role of inducing acute graft-versus-host disease (aGVHD) during transplantation in preventing relapse.. METHODS: Thirty adult patients with refractory or relapsed leukemia were acute lymphoblastic leukemia (n=16), acute myelogenous leukemia (n=10), and acute mixed leukemia (n=4). They were in first complete remission (n=4), second complete remission (n=9), partly remission (n=12), and non-response (n=5) at the time of transplantation. Patients underwent allogeneic peripheral blood stem cell transplantation (allo-PBSCT) from HLA-identical siblings (n=21), mismatched siblings donors (n=3), and allogeneic bone marrow transplantation (n=5) or allo-PBSCT (n=1) from unrelated HLA matched donors. All patients received myeloablative ...
TY - JOUR. T1 - Calcineurin inhibitor-induced irreversible neuropathic pain after allogeneic hematopoietic stem cell transplantation. AU - Fujii, Nobuharu. AU - Ikeda, Kazuma. AU - Koyama, Motoko. AU - Aoyama, Kazutoshi. AU - Masunari, Taro. AU - Kondo, Eisei. AU - Matsuzaki, Takashi. AU - Mizobuchi, Satoshi. AU - Hiraki, Akio. AU - Teshima, Takanori. AU - Shinagawa, Katsuji. AU - Ishimaru, Fumihiko. AU - Tanimoto, Mitsune. PY - 2006/6/1. Y1 - 2006/6/1. N2 - The calcineurin inhibitors (CIs) cyclosporine A and tacrolimus are essential for graft-versus-host disease prophylaxis but are associated with adverse effects, including neurotoxicity. We report a case of irreversible CI-induced neuropathic pain following allogeneic hematopoietic stem cell transplantation. The patient developed dysesthesia, electric shock-like pain, and severe itching followed by intractable analgesic-resistant pain in the lower extremities. There were no abnormal radiographic findings, and there was no improvement with a ...
Purpose of reviewCytomegalovirus (CMV) infection is a common opportunistic infection after allogeneic haematopoietic stem cell transplantation (HSCT). CMV surveillance-preemptive therapy is the current preferred approach for preventing CMV disease after HSCT. In contrast, antiviral prophylaxis is no
TY - JOUR. T1 - Infectious complications following nonmyeloablative allogeneic hematopoietic stem cell transplantation. AU - Busca, Alessandro. AU - Locatelli, F.. AU - Barbui, A.. AU - Ghisetti, V.. AU - Cirillo, D.. AU - Serra, R.. AU - Audisio, E.. AU - Falda, M.. PY - 2003/9. Y1 - 2003/9. N2 - Nonmyeloablative hematopoietic stem cell transplantation (NST) has been explored in hematological malignancies and solid tumors in an attempt to minimize treatment-related toxicity. Whether this approach is associated with reduced risk of infectious complications is unclear. The aim of the current study was to evaluate the infectious complications in a series of 32 consecutive adult patients who received NSTat our institution. Peripheral blood stem cell grafts (n = 30) or marrow grafts (n = 2) were infused from human leukocyte antibody (HLA)·matched sibling (n = 30), partially matched related (n = 1), or unrelated (n = 1) donors. Neutropenia developed in two-thirds of patients and lasted 16 days. ...
The University of Washington and Fred Hutchinson Cancer Research Center have been awarded a four-year $4.8 million contract by the National Human Genome Research Institute (NHGRI) of the National Inst...
Highly diverse bacterial populations inhabit the gastrointestinal tract and modulate host inflammation and promote immune tolerance. In allogeneic hematopoietic stem cell transplantation (allo-HSCT), the gastrointestinal mucosa is damaged, and colonizing bacteria are impacted, leading to an impaired intestinal microbiota with reduced diversity. We examined the impact of intestinal diversity on subsequent mortality outcomes following transplantation. Fecal specimens were collected from 80 recipients of allo-HSCT at the time of stem cell engraftment. Bacterial 16S rRNA gene sequences were characterized, and microbial diversity was estimated using the inverse Simpson index. Subjects were classified into high, intermediate, and low diversity groups, and assessed for differences in outcomes. Mortality outcomes were significantly worse in patients with lower intestinal diversity; overall survival at three years was 36%, 60%, and 67% for low, intermediate, and high diversity groups, respectively ...
TY - JOUR. T1 - Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation. AU - Lupo-Stanghellini, Maria Teresa. AU - Provasi, Elena. AU - Bondanza, Attilio. AU - Ciceri, Fabio. AU - Bordignon, Claudio. AU - Bonini, Chiara. PY - 2010/3/1. Y1 - 2010/3/1. N2 - Allogeneic hematopoietic stem cell transplantation (allo-SCT) from an HLA-matched related or unrelated donor is a curative option for patients with high-risk hematological diseases. In the absence of a matched donor, patients have been offered investigational transplantation strategies such as umbilical cord blood SCT or family haploidentical SCT. Besides the activity of the conditioning regimen, most of the antileukemic potential of allo-SCT relies on alloreactivity, promoted by donor lymphocytes reacting against patient-specific antigens, such as minor and major histocompatibility antigens, ultimately translating into cancer immunotherapy. Unfortunately, alloreactivity is also responsible for the most ...
TY - JOUR. T1 - Effects of calcineurin inhibitors on sodium excretion in recipients of allogeneic hematopoietic stem cell transplantation. AU - Saburi, Masuho. AU - Kohashi, Sumiko. AU - Kato, Jun. AU - Koda, Yuya. AU - Sakurai, Masatoshi. AU - Toyama, Takaaki. AU - Kikuchi, Taku. AU - Karigane, Daiki. AU - Yuda, Sayako. AU - Yamane, Yusuke. AU - Hashida, Risa. AU - Abe, Ryohei. AU - Nakazato, Tomonori. AU - Hirahashi, Junichi. AU - Ogata, Masao. AU - Okamoto, Shinichiro. AU - Mori, Takehiko. PY - 2017/5/17. Y1 - 2017/5/17. N2 - Calcineurin inhibitors (CIs) such as cyclosporine A (CSA) and tacrolimus often cause renal dysfunction, resulting in increased serum creatinine, hyperkalemia, and hyperuricemia. However, the effects of CIs on sodium excretion have not been fully elucidated. We retrospectively evaluated the effects of CI administration on sodium excretion in recipients of allogeneic hematopoietic stem cell transplantation (HSCT). Fifty consecutive recipients each of allogeneic HSCT ...
EV Morozova, YuYu Vlasova, MV Barabanshchikova, NN Mamaev, IM Barkhatov, AL Alyanskii, EI Darskaya, MV Vladovskaya, SN Bondarenko, IS Moiseev, BV Afanasyev RM Gorbacheva Scientific Research Institute of Pediatric Oncology, Hematology and Transplantation; IP Pavlov First Saint Petersburg State Medical University, 6/8 Lva Tolstogo str., Saint Petersburg, Russian Federation, 197022 For correspondence: Elena Vladislavovna Morozova, MD, PhD, 6/8 Lva Tolstogo str., Saint Petersburg, Russian Federation, 197022; e-mail: [email protected] For citation: Morozova EV, Vlasova YuYu, Barabanshchikova MV, et al. Chronic Myeloid Leukemia: Role of Allogeneic Hematopoietic Stem Cell Transplantation in the Era of Tyrosine Kinase Inhibitors. Clinical oncohematology. 2020;13(2):193-8 (In Russ). DOI: 10.21320/2500-2139-2020-13-2-193-198 ABSTRACT Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a radical method of chronic myeloid leukemia (CML) treatment. In the 1990s CML became the most frequent
Extramedullary relapse of AML following allogeneic HSCT remains a poorly understood post-HSCT outcome. The incidence of extramedullary relapse in this study (10%) is consistent with previously reported rates over the past 35 years despite many changes in allogeneic HSCT practices.21,22 Although it is possible that patients with risk factors for extramedullary relapse are currently more likely to undergo allogeneic HSCT than they were in the past, it is more likely that the stable incidence reflects a lack of progress in this scenario. In this series of patients, we confirmed that the increased risk of extramedullary relapse for most previously reported risk factors, including pre-HSCT extramedullary disease, FAB M4/M5 AML, and advanced disease status, also apply to the post-HSCT setting.10,20 We did not, however, find there was an increased risk associated with CD56 or T-cell marker expression. While not surprising, our finding that patients with advanced disease status or high risk cytogenetics ...
Allogeneic haematopoietic stem cell transplantation remains the only curative treatment of myelofibrosis with myeloid metaplasia (MMM). Previous reports have indicated significant treatment-related mortality (TRM) for patients transplanted after myeloablative conditioning but superior survival has been reported after reduced-intensity conditioning (RIC). We report the results of a survey of all allogeneic transplantations for MMM performed in Sweden at six transplant units between 1982 and 2004. Twenty-seven patients were transplanted, 17 with a myeloablative conditioning regimen and 10 with RIC. The median age was 50 years (5-63 years) at transplantation. After a median follow up of 55 months, 20 patients are alive. TRM was 10% in the RIC group and 30% in the myeloablative group. There was no difference in survival for high or low-risk patients according to Cervantes score or between sibling and unrelated donor transplantations. © 2006 The Authors.. ...
Ringden, O.; Labopin, M.; Schmid, C.; Sadeghi, B.; Polge, E.; Tischer, J.; Ganser, A.; Michallet, M.; Kanz, L.; Schwerdtfeger, R.; Nagler, A.; Mohty, M. (2016): Sequential chemotherapy followed by reduced intensity conditioning and allogeneic hematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukemia (AML): a survey from the Acute Leukemia Working Party of EBMT. In: Bone Marrow Transplantation, Vol. 51: S476-S477 ...
TY - JOUR. T1 - Vitamin D level after allogeneic hematopoietic stem cell transplant. AU - Sproat, Lisa. AU - Bolwell, Brian. AU - Rybicki, Lisa. AU - Dean, Robert. AU - Sobecks, Ronald. AU - Pohlman, Brad. AU - Andresen, Steven. AU - Sweetenham, John. AU - Copelan, Edward. AU - Kalaycio, Matt. PY - 2011/7. Y1 - 2011/7. N2 - Vitamin D (VD) deficiency can cause osteomalacia, bone pain, muscle weakness, fatigue, and increased risk of fracture, and may precipitate or exacerbate osteopenia and osteoporosis. Patients receiving treatment for acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) may have limited exposure to sunlight and often experience gastrointestinal side effects that may decrease their ability to maintain an adequate VD level. We hypothesized that patients with AML and ALL would have a low VD level after allogeneic hematopoietic cell transplant (HCT), and that these patients would have a high incidence of osteoporosis/osteopenia. We therefore studied the incidence of ...
The purpose of this study is to evaluate the outcome of imatinib combined with reduced-intensity allogeneic hematopoietic stem cell transplantation versus
PubMed journal article: Effect of graft source on unrelated donor hemopoietic stem cell transplantation in adults with acute myeloid leukemia after reduced-intensity or nonmyeloablative conditioning: a study from the Société Francaise de Greffe de Moelle et de Thérapie Cellulaire. Download Prime PubMed App to iPhone, iPad, or Android
Introduction. Cyclosporin (CSA) is commonly used as graft vs host disease (GvHD) prophylaxis in allogeneic haematopoietic stem cell transplant (alloHSCT) recipients. The usual IV dose is 3mg/kg and the recommended oral dose at switching is 3mg/kg BD in the pre-posaconazole era (Inoue et al. 2014). Posaconazole is now commonly used as antifungal prophylaxis in this context; it increases CSA levels through inhibition of the cytochrome involved in CSA metabolism (Sánchez-Ortega et al. 2012). We evaluated CSA-related toxicity after switch from IV to oral CSA in alloHSCT recipients receiving posaconazole with the aim of defining the optimal weight based oral dose.. Methods. A retrospective audit was performed of adult alloHSCT patients between October 2015 and October 2017 who received IV and then oral CSA together with posaconazole prophylaxis. Posaconazole was commenced during conditioning and continued at 300mg IV or oral daily according to gastrointestinal tolerance; patients with levels below ...
These experiments explored mechanisms of control of acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation using a murine model of MHC-matched, minor histocompatibility antigen mismatched transplantation. The central hypothesis examined was that addition of active vaccination against leukemia cells would substantially increase the effectiveness of allogeneic donor lymphocyte infusion against ALL present in the host after transplant. While vaccination did increase the magnitude of type I T cell responses against leukemia cells associated with donor lymphocyte infusion, it did not lead to substantial improvement in long term survival. Analysis of immunological mechanisms of leukemia progression demonstrated that the failure of vaccination was not due to antigen loss in leukemia cells. However, analysis of survival provided surprising findings that, in addition to very modest type I T cell responses, a B cell response that produced antibodies that bind leukemia ...
Yi-Bin Chen, Massachusetts General Hospital, Boston, US, and colleagues explored the potential benefits of coadministration of vedolizumab with standard GvHD prophylaxis in a phase Ib study
TY - JOUR. T1 - Hepatitis C virus (HCV) infection in bone marrow transplant patients after transfusions from anti-HCV-positive blood donors. AU - Shuhart, M. C.. AU - Myerson, D.. AU - Spurgeon, C. L.. AU - Bevan, C. A.. AU - Sayers, M. H.. AU - McDonald, G. B.. PY - 1996/4/1. Y1 - 1996/4/1. N2 - In March 1992, 12 bone marrow transplant patients at the Fred Hutchinson Cancer Research Center received blood components from donors who were anti-HCV-nonreactive by first generation ELISA but whose serum later tested anti-HCV-reactive to a second generation ELISA. All these blood components were further tested for anti-HCV using a second-generation RIBA and for HCV RNA by polymerase chain reaction. Recipient sera were tested for HCV RNA prior to and following blood component infusion. Blood components from four donors were positive for HCV RNA. All recipients of HCV RNA-positive blood components became viremic on the first day tested post-infusion. In addition, two recipients of HCV RNA-negative blood ...
Hematopoietic stem cell transplantation (HSCT) is an established treatment for a variety of malignant diseases, as well as a small proportion of non-malignant disorders. The treatment before the HSCT (called conditioning) can be either myeloablative (MAC) or given with reduced intensity (RIC). MAC is associated with high toxicity due to high doses of chemotherapy with or without total body irradiation (TBI), and is used in both autologous and allogeneic HSCT. In autologous HSCT the patient is the donor, and in allogeneic HSCT the donor is a sibling or an unrelated donor. RIC regimens are associated with reduced toxicity and are only for patients undergoing allogeneic HSCT. Both autologous and allogeneic HSCT have a strong effect on the patients health-related quality of life (HRQL). The two studies in this thesis were initiated when RIC was introduced at a hematological department in south-east Sweden in 2001. The overall purpose was to evaluate HRQL in patients undergoing HSCT. The studies ...
TY - JOUR. T1 - Reduced intensity conditioning in allogeneic stem cell transplantation for AML with Down syndrome. AU - Muramatsu, Hideki. AU - Sakaguchi, Hirotoshi. AU - Taga, Takashi. AU - Tabuchi, Ken. AU - Adachi, Souichi. AU - Inoue, Masami. AU - Kitoh, Toshiyuki. AU - Suminoe, Aiko. AU - Yabe, Hiromasa. AU - Azuma, Eichi. AU - Shioda, Yoko. AU - Ogawa, Atsushi. AU - Kinoshita, Akitoshi. AU - Kigasawa, Hisato. AU - Osugi, Yuko. AU - Koike, Kazutoshi. AU - Kawa, Keisei. AU - Kato, Koji. AU - Atsuta, Yoshiko. AU - Kudo, Kazuko. PY - 2014/5. Y1 - 2014/5. N2 - Allogeneic hematopoietic stem cell transplantation (HSCT) has not been widely used in patients with acute myeloid leukemia (AML) and Down syndrome (DS) due to fear of transplantation-related toxicity. A retrospective analysis of the outcome of allogeneic HSCT was conducted in 15 patients with AML and DS. The five patients transplanted with the reduced intensity conditioning (4 in complete remission (CR) and 1 in non-CR) had a ...
Gonadal function after allogenic bone marrow transplantation for thalassaemia. Social integration of the older thalassaemic patient
指紋 深入研究「Effect of allogeneic hematopoietic stem cell transplantation from matched siblings or unrelated donors during the first complete remission in patients with cytogenetically normal acute myeloid leukemia」主題。共同形成了獨特的指紋。 ...
Rabbit polyclonal to Dynamin-1.Dynamins represent one of the subfamilies of GTP-binding proteins.These proteins share considerable sequence similarity over the N-terminal portion of the molecule, which contains the GTPase domain.Dynamins are associated with microtubules.. black individuals from the prior research had been lost to check out up. Three brand-new alloHSCT recipients had been enrolled. We contacted five entitled alloHSCT recipients to sign up the three brand-new alloHSCT SDZ 220-581 Ammonium salt individuals. HSCT and matched-control individuals had been enrolled more than a 15-month period. The matched-control and alloHSCT characteristics are summarized in Desk 1. All individuals had been Caucasian. AlloHSCT was connected with postponed maturation. Elevation Z-scores had been markedly low in alloHSCT individuals while BMI Z-scores didnt differ considerably. AlloHSCT sitting elevation relative to elevation was considerably lower in comparison to handles (p ...
Hematopoietic Cell Transplantation, 2nd ed. Blackwell Science, London, 1999, pp. 823-834. 3. Forman SJ, Krance RA, ODonnell MR, et al. Bone marrow transplantation for acute nonlymphoblastic leukemia during first complete remission. An analysis of prognostic factors. Transplantation 1987;43:650-653. 4. Mehta J, Powles R, Treleaven J, et al. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088. 59. Appelbaum FR, Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia 1998;12 (suppl. 1):S25-S29. Chapter 2 / Allogeneic BMT for AML 27 60. Fefer A. Graft-versus-tumor responses. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Cell Transplantation, 2nd ed. Blackwell ...
Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy Olga Blau, Igor Wolfgang Blau Department of Hematology, Oncology and Tumor Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany Abstract: Myelodysplastic syndrome (MDS) is a heterogeneous group of myeloid disorders. MDS remains a disease of elderly patients; moreover, the incidence of high risk MDS is proportionally greater in elderly patients, with increased frequency of secondary acute myeloid leukemia, as well as adverse cytogenetic abnormalities. Allogeneic stem cell transplantation is a therapeutic approach with known curative potential for patients with MDS that allows the achievement of long-term disease control. Numerous controversies still exist regarding transplantation in MDS: timing of transplantation, disease status at transplantation and comorbidity, conditioning intensity, pretransplant therapy, and stem cell source. Various transplant
Background: Renal dysfunction after allogeneic hematopoietic stem cell transplantation (HSCT) has been increasingly reported. However, there are few reports on the changes of the estimated glomerular filtration rate (eGFR) in long-term survivors after allogeneic HSCT. Patients and methods: The medical records at Seoul St. Marys Hospital in Korea were reviewed to identify all adult (, 18 years of age) patients who had undergone high-dose chemotherapy and allogeneic HSCT between January 2001 and December 2005. Among these patients, those with , 5 years of follow-up and relapse within 5 years after HSCT were excluded. 85 patients were enrolled. Results: The mean follow-up was 76.0 +/- 13.5 months. The eGFR recorded 3 months after HSCT was significantly decreased compared with the eGFR recorded before HSCT. Subsequently, early decreased eGFR was maintained during the 60 months after HSCT. Multivariate analysis showed that acute kidney injury (AKI) during HSCT, hypertension (HTN) and eGFR before ...
Results from a randomized, double-blind, placebo-controlled trial show that letermovir protects from viral infection in CMV-seropositive individuals following allogeneic hematopoietic cell transplantation.
Antifungal Prophylaxis with Posaconazole in Allogeneic Hematopoietic Stem Cell Transplantation Using Sirolimus for Prevention of Graft-Versus-Host DiseaseConference abstracts...
Assessment of Allogeneic Hematopoietic Stem Cell Transplantation in Medicare Beneficiaries with Myelodysplastic Syndrome and Related disorders - Part I ...
TY - JOUR. T1 - Bone marrow engraftment and GVHD following bone marrow transplantation across a concordant xenogeneic barrier (mouse to rat). AU - Li, H.. AU - Selvaggi, G.. AU - Ricordi, C.. AU - Inverardi, L.. PY - 1997/7/7. Y1 - 1997/7/7. UR - http://www.scopus.com/inward/record.url?scp=0030979295&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0030979295&partnerID=8YFLogxK. U2 - 10.1016/S0041-1345(97)00288-1. DO - 10.1016/S0041-1345(97)00288-1. M3 - Article. C2 - 9193584. AN - SCOPUS:0030979295. VL - 29. SP - 2190. EP - 2191. JO - Transplantation Proceedings. JF - Transplantation Proceedings. SN - 0041-1345. IS - 4. ER - ...
Xu, L.,Zhu, H. L.,Hu, J. D.,et al. SUPERIORITY OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION TO NILOTINIB & DASATINIB FOR ADULT PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN THE ACCELERATED PHASE[J]. HAEMATOLOGICA,2015,suppl.1:434-434 ...
Full text of Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation : Models in Discovery and Translation 1st ed. (2013) Gerard Socie and B.R. Blazar is part of the ScienceDirect eBook Collection. For USC users only. Requires USC network connection.. ...
This retrospective report compared the results of graft source on outcome after allogeneic stem cell transplantation (allo-SCT) in patients with hematologic malignancies receiving a reduced intensity conditioning (RIC) regimen. A total of 152 patients received either a RIC allo-SCT using a 9/10 mismatched unrelated donor (MisMUD, n=42) or a double unrelated umbilical cord blood (dUCB, n=110) graft. With a median follow-up of 30.3 months, the cumulative incidence of non-relapse mortality was 26% in the dUCB group versus 24% in the MisMUD group (P=0.95). Grade 3-4 acute graft-versus-host disease (GVHD) incidence was 19.7% in the dUCB group versus 21.4% in the MisMUD group (P=0.83). The cumulative incidence of extensive chronic GVHD at 2 years was 6.4% in the dUCB group versus 21.4% in the MisMUD group (P=0.02). The Kaplan-Meier estimate of overall survival at 2 years was comparable between both groups (52.3% (95% confidence interval (CI), 42.1-61.5%) in the dUCB group versus 47.9% (95% CI, 31.6-62.4%) in
Despite the curative potential of allogeneic stem cell transplantation (allo-SCT) in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), many patients will relapse. Until...
Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is still the only curative treatment for Chronic Myelogenous Leukemia (CML) at present. For only few patients having suitably matched donor, transplantations with stem cells from HLA mismatched related family donors have been increasingly used. But Used of HLA mismatched HCT involves crossing histocompatibility barriers, it has been limited by high risk of severe graft-versus-host disease (GVHD), graft rejection and delayed or incomplete immune reconstruction. The inducing immune tolerance and modulate allogeneic reaction may play a role in avoiding severe GVHD in HLA-mismatched HSCT. Our goal in this study was to investigate the feasibility and clinical value of this approach in the treatment of CML. From February 1999 to February 2008, 55 patients with CML, aged 8 to 52 years (median age 29 years), received HSCT from HLA two or three loci mismatched donor, 18 were in chronic phase, 19 were in accelerated phase, 18 were in blast ...
ISBN 978-1-4377-1753-2. Tenenhouse HS (February 1999). "X-linked hypophosphataemia: a homologous disorder in humans and mice". ... Nephrology, Dialysis, Transplantation. 14 (2): 333-41. doi:10.1093/ndt/14.2.333. PMID 10069185. Sodium-Phosphate+Cotransporter+ ...
Sen, PK; Parulkar, GB; Panday, SR; Kinare, SG (1965). "Homologous canine heart transplantation: a preliminary report of 100 ... Cooper, D. K. C. (1 July 1969). "Transplantation of the heart and both lungs: I. Historical review". Thorax. 24 (4): 383-390. ... Kalra, Aakshi; Seth, Sandeep; Hote, Milind Padmaker; Airan, Balram (1 May 2016). "The story of heart transplantation: From cape ...
Heart transplantation in Chagas' disease. 10 years after the initial experience. Circulation. 1996 Oct 15;94(8):1815-7. PMID ... Results of replacement of cardiac valves by homologous dura mater valves. Chest. 1975 Jun;67(6):706-10. PMID 123848 Barbero ... He is internationally known for performing the first heart transplantation in Latin America (and the third in the world) in ... Experience on three cases of human heart transplantation. Laval Med. 1970 Feb;41(2):149-54. PMID 4929483 Losardo RJ et al. ...
2. Vascularization of autologous and homologous implants of cortical bone in rats". The British Journal of Experimental ... Transplantation. 11 (2): 128-134. doi:10.1097/00007890-197102000-00004. PMID 5578737.(subscription required) Heslop, Barbara F ... Manifestations of immunological tolerance to implants of homologous cortical bone in rats". The British Journal of Experimental ... A comparison of autologous and homologous bone implants with reference to osteocyte survival, osteogenesis and host reaction". ...
Milachowski, KA; Weismeier, K; Wirth, CJ (1989). "Homologous meniscus transplantation. Experimental and clinical results". ... Early reports of meniscus transplantation done in arthritic knees suggested a higher incidence of transplantation failure if ... Meniscal transplantation is a novel surgical technique designed to improve the biology and biomechanics of a meniscus deficient ... Meniscal transplantation is technically difficult, as it must be sized accurately for each person, positioned properly and ...
... protein consists of six domains: A1-A2-B-A3-C1-C2, and is homologous to factor V. The A domains are homologous to ... Hemophilia A has been corrected by liver transplantation. Transplanting hepatocytes was ineffective, but liver endothelial ...
... has been applied to renal transplantation, liver transplantation and lung transplantation. It is an ... Murray R, Diefenbach WCL (1953). "Effect of heat on the agent of homologous serum hepatitis". Proc Soc Exp Biol Med. 84 (1): ... "The case for normothermic machine perfusion in liver transplantation: Ceresa et al". Liver Transplantation. 24 (2): 269-275. ... Machine perfusion (MP) is a technique used in organ transplantation as a means of preserving the organs which are to be ...
Humanized models also aid in testing new therapies Studying allograft rejection after pancreatic islet transplantation therapy ... homologous to IL2RG in humans). IL2Rγ is a common component of the cell surface receptors that bind and transduce signals from ... or for long-term transplantation studies. The Il2rgtm1Wjl targeted mutationb is a complete null mutation in the gene encoding ...
Both structures are considered as homologous, nevertheless there is still a debate on whether this is true or not. This view is ... and the sharing of strong axis-inducing properties upon transplantation. Cell fate studies have revealed that also the overall ... the amniote primitive streak and the amphibian blastopore are homologous structures, meaning that they have evolved from one ...
... meaning nothing homologous with LDV in mice has been found in another species. LDV was discovered in 1960 by Dr. Vernon Riley ... activity within three days of the transplantation. This occurred even before the tumors were obvious clinically. In further ...
... awarded a Hunterian Professorship of the Royal College of Surgeons of England for his lecture The transplantation of homologous ... The Transplantation of Tissues and Organs. Charles C. Thomas. Springfield, Illinois 1960. The One and the Many: Edwin Stevens ... "History of Kidney Transplantation in Edinburgh". Archived from the original on 6 February 2009. Retrieved 30 November 2008. " ... As a major part of his research, Woodruff served as the honorary director of a Research Group on Transplantation established by ...
From 1960 to 1965 Dausset worked primarily on improving organ transplantation techniques and the mechanisms involved in ... and the discovery that Hu-1 is homologous to the mouse H-2 complex, which also functions in histocompatibility. Toward the end ... transplantation immunogenetics research unit. Dausset founded France Transplant and France Greffe de Moelle, which brings ... a conclusion which would in time have profound effects on the transplantation process. In the years to come, Dausset continued ...
Canadian Transplantation Society [4], XVII World Congress of The Transplantation Society Inc. [5], is a Fellow of the Royal ... Guttmann, R.D., Aust, J.B.: Acquired tolerance to homografts produced by homologous spleen cell injection in adult mice. Nature ... now called American Society of Transplantation. [16](1982). Co-founder and president of the Canadian Transplantation Society [ ... Transplantation Reviews 6:189-193, 1992. cited in: Human Rights Watch Report on Judicial Execution in China.[19] Guttmann, R.D ...
... base pair birth defect bone marrow transplantation cancer candidate gene carcinoma carrier cDNA library cell centimorgan ... line haploid haploinsufficiency hematopoietic stem cell heterozygous highly conserved sequence holoprosencephaly homologous ...
... which has a similar structure to red pulp and is presumed homologous with the spleen of higher vertebrates. In mice the spleen ... Spleen Laparoscopic view of human spleen Asplenia with cardiovascular anomalies Marginal zone Spleen transplantation σπλήν[ ...
H-13, a new histocompatibility locus in the fifth linkage group". Transplantation. 5 (3): 492-503. doi:10.1097/00007890- ... as well as proteins with homologous leader sequences that are essential components of the general secretion pathway found in a ... from the SPP protein serves as minor histocompatibility antigen HM13 that plays a role in transplant rejection The homologous ...
There are homologous tissues to the endosternite cartilage in other arthropods. The embryos of Limulus polyphemus express ColA ... This property allows for the transplantation of cartilage from one individual to another without fear of tissue rejection. ...
"Epiretinal Transplantation of Human Bone Marrow Mesenchymal Stem Cells Rescues Retinal and Vision Function in a Rat Model of ... "Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats". Nature Medicine. 4 (7): 814- ...
Experiments show that transplantation of other types of veto cells along with megadose haploidentical HSCT allows to reduce the ... Immunological methods utilize antibodies, either alone, in conjunction with homologous, heterologous, or rabbit complement ... This procedure is called 'megadose transplantation' and it prevents rejection because the stem cells have an ability (i.e. veto ... TCD is heavily used in haploidentical stem cell transplantation (HSCT), a process in which cancer patients receive an infusion ...
There are three main types of disease models: homologous, isomorphic and predictive. Homologous animals have the same causes, ... For example, the results have included the near-eradication of polio and the development of organ transplantation, and have ... The cell cycle in a simple yeast is very similar to the cell cycle in humans and is regulated by homologous proteins. The fruit ... Animal models can be classified as homologous, isomorphic or predictive. Animal models can also be more broadly classified into ...
"NHEJ1 non-homologous end joining factor 1 [Homo sapiens (human)] - Gene - NCBI". www.ncbi.nlm.nih.gov. Retrieved 2017-07-13. " ... one finds that treatment with allogeneic hematopoietic stem cell transplantation, which are stem cells that bring about other ... is 219,075,324 to 219,160,865 The pathophysiology of Cernunnos deficiency begins with normal function of Non-homologous end- ...
"ABO COMPATIBILITY AND ACUTE GRAFT-VERSUS-HOST DISEASE FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION". Transplantation. 45 (6 ... "controlled at a single gene locus or by two or more very closely linked homologous genes with little or no observable ... It is also used before hematopoietic stem cell transplantation, as it may be responsible for some cases of acute graft-versus- ...
For instance, human foreskin fibroblasts, one type of somatic cell, use non-homologous end joining (NHEJ), an error prone DNA ... On January 23, 2009, Phase I clinical trials for transplantation of oligodendrocytes (a cell type of the brain and spinal cord ... The major concern with the possible transplantation of ESC into patients as therapies is their ability to form tumors including ... Thus, mouse ES cells predominantly use high fidelity homologous recombinational repair (HRR) to repair DSBs. This type of ...
Medawar, P. B. (2017-01-04). "Immunity to Homologous Grafted Skin. III. The Fate of Skin Homographs Transplanted to the Brain, ... In another study on type II diabetic and obese mice, the transplantation of microencapsulated Sertoli cells in the subcutaneous ... Medically, a cornea transplant takes advantage of this, as does knee meniscal transplantation. Antigens from immune privileged ... There is great potential for use of molecular mechanisms present in immune privileged sites in transplantations, especially ...
1989). "20 KDa homologous restriction factor of complement resembles T cell activating protein". Biochem. Biophys. Res. Commun ... Transplantation. 57 (10): 1494-501. doi:10.1097/00007890-199405000-00017. PMID 7515200. CD59+Antigen at the US National Library ... 1990). "Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal ... regulates the action of the complement membrane attack complex on homologous cells". J. Exp. Med. 170 (3): 637-654. doi:10.1084 ...
The CtlP and Mre11 nuclease complex are essential for accurate processing and repair of double-strand breaks during homologous ... The basis for clonal aging was clarified by transplantation experiments of Aufderheide in 1986. When macronuclei of clonally ...
However, homologous recombinational repair of DNA double-strand breaks mediated by BRCA1 and ATM weakens with age in oocytes of ... condition their ovarian tissue is cryopreserved for fertility preservation.Alternately to the autologous transplantation, the ... such as homologous recombination. Some algae and the oomycetes produce eggs in oogonia. In the brown alga Fucus, all four egg ... the germline during the decades long period in humans between early oocytogenesis and the stage of meiosis in which homologous ...
Transplantation of a single neoblast to a fatally injured animal has been shown to rescue the animal An analysis of the genome ... Two protein components have been found within the chromatoid bodies DjCBC-1 and SpolTud-1, which are homologous to proteins ... Transplantation of just one clonogenic neoblast, a worm with no neoblast, restored all the organism's cells. One single ... neoblast can regenerate an entire irradiated animal that has been rendered incapable of regeneration following transplantation ...
Non-homologous end joining (NHEJ) is a pathway that repairs double-strand breaks in DNA. NHEJ is referred to as "non-homologous ... Hematopoietic stem cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived ... Hematopoietic stem cell transplantation remains a dangerous procedure with many possible complications; it is reserved for ... This phenomenon is used in bone marrow transplantation, when a small number of Hematopoietic stem cells reconstitute the ...
During meiosis homologous chromosomes pair with each other and undergo a DNA repair process in which DNA damage is removed and ... such as those who have undergone haematopoietic stem cell transplantation or are otherwise undergoing immunosuppression ... All in all, homologous recombination provides more specificity when creating a mutant strain. Depending on the mutant, ... It was found that disrupting (knockout or RNAi silencing) ku70 homologue can increase gene targeting via increased homologous ...
Homologous chromosome. *Isochromosome. *Satellite chromosome. *Centromere position *Metacentric. *Submetacentric. *Telocentric ...
The chromosomes of neighboring pairs are partially homologous, such that a chain is formed during mitosis.[18] The first X ... Transplantation. 17 (4): 346-354. doi:10.1097/00007890-197404000-00003. ISSN 0041-1337. PMID 4823382. S2CID 35983351.. ... Monotremes possess four or five (platypus) pairs of XY sex chromosomes, each pair consisting of sex chromosomes with homologous ... homologous, chromosome. When errors occur, it can use other parts of itself as a template to correct them.[citation needed] ...
Organ transplantation Transplantation of retinas has been attempted, but without much success. At MIT, The University of ... It is arguable that this difference shows that vertebrate and cephalopod eyes are not homologous but have evolved separately. ... Successful photoreceptor transplantation, MIT Technology Review, November 2006. How stem cells might restore sight Technology ... "Retinal repair by transplantation of photoreceptor precursors" (PDF). Nature. 444 (7116): 203-7. Bibcode:2006Natur.444..203M ...
... non-homologous end joining and homologous recombinational repair (HRR) (see chart in DNA repair) and reference.[15] Only HRR ... 2008). 'Metabolic Management - Organ Procurement and Preservation For Transplantation. New York: Landes Bioscience Springer. ... Experimentally, mutation rates increase substantially in cells defective in DNA mismatch repair[16][17] or in Homologous ... The HRR pathway requires that a second homologous chromosome be available to allow recovery of the information lost by the ...
Milland J, Sandrin MS (December 2006). "ABO blood group and related antigens, natural antibodies and transplantation". Tissue ... The variable domain exon is rejoined through a process called non-homologous end joining (NHEJ) to the desired constant region ...
Berthold AA (1849). "Transplantation der Hoden". Arch. Anat. Physiol. Wiss. Med. 16: 42-6.. ... Some forms of vitamin D, such as calcitriol, are steroid-like and bind to homologous receptors, but lack the characteristic ...
The collecting ducts from each cluster of nephrons usually drain into an archinephric duct, which is homologous with the vas ... Dialysis and kidney transplantation are used to treat kidney failure; one (or both sequentially) of these are almost always ... Renal replacement therapy, in the form of dialysis or kidney transplantation, is indicated when the glomerular filtration rate ... these are never homologous with the kidneys of vertebrates, and are more accurately referred to by other names, such as ...
"Cancer Spread By Transplantation Extremely Rare: In Very Rare Case, Woman Develops Leukemia from Liver Transplant". ... "Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine ...
This is likely due to homologous chromosomes with arms of unequal lengths causing instability during meiosis.[19] ... 2001). "Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: ... Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation". ...
Also genetically modified pigs have been bred with the aim of increasing the success of pig to human organ transplantation.[90] ... The technique of gene targeting uses homologous recombination to make desired changes to a specific endogenous gene. This tends ... and use the cell's endogenous mechanisms to repair the induced break by the natural processes of homologous recombination and ...
MacCallum FO (1947). "Homologous serum hepatitis". Lancet. 2: 691-692. doi:10.1016/S0140-6736(47)90722-8.. ... Schilsky ML (2013). "Hepatitis B "360"". Transplantation Proceedings. 45 (3): 982-985. doi:10.1016/j.transproceed.2013.02.099. ... Kerkar N (2005). "Hepatitis B in children: complexities in management". Pediatric transplantation. 9 (5): 685-691. doi:10.1111/ ... Terrault N, Roche B, Samuel D (July 2005). "Management of the hepatitis B virus in the liver transplantation setting: a ...
... but they have one that is considered homologous to it. The hippocampus, as pointed out above, is in essence part of the ... Experiments using intrahippocampal transplantation of hippocampal cells in primates with neurotoxic lesions of the hippocampus ...
bone marrow transplantation. *angiogenesis for cardiovascular diseases. See also[edit]. *Angiogenesis. *Bone growth factor ...
... homologous, chromosome. When errors occur, it can use other parts of itself as a template to correct them.[citation needed] ... Transplantation. 17 (4): 346-354. doi:10.1097/00007890-197404000-00003. ISSN 0041-1337.. ...
In mice the MHC locus known as IA is homologous to human HLA DQ. Several autoimmune diseases that occur in humans that are ... The name 'HLA DQ' originally describes a transplantation antigen of MHC class II category of the major histocompatibility ... complex of humans; however, this status is an artifact of the early era of organ transplantation. ...
Mitotic crossover may enable recombination, i.e., an exchange of genetic material between homologous chromosomes. The ... It excretes Ciclosporin, which, as well as being given during Organ transplantation to prevent rejection, is also prescribed ...
Titus et al.[19] also found that expression of 4 key genes necessary for homologous recombinational repair of DNA double-strand ... Lan C, Xiao W, Xiao-Hui D, Chun-Yan H, Hong-Ling Y (December 2008). "Tissue culture before transplantation of frozen-thawed ... However, they develop in a very different way in most invertebrates than they do in vertebrates, and are not truly homologous.[ ... The BRCA1 protein plays a key role in a type of DNA repair termed homologous recombinational repair that is the only known ...
Mutation rates strongly increase in cells defective in DNA mismatch repair[34][35] or in homologous recombinational repair (HRR ... "The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation". N. Engl. J. Med. 332 (1 ...
E. DonnallE.D. Thomas E. DonnallE.D., A history of haemopoietic cell transplantation, „British Journal of Haematology", 1999 . ... An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion ... Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. „J Clin Oncol". 28 (23), s ... Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. „ ...
La mobilisation est utilisée comme une source de cellules souches hématopoïétiques pour la transplantation de moelle (par ... Direct association of Csk homologous kinase (CHK) with the diphosphorylated site Tyr568/570 of the activated c-KIT in ...
Indeed, since the sinus venosus is incorporated into the right atrium in amniotes, it is likely homologous with the SA node. In ... The first successful heart transplantation was performed in 1967 by the South African surgeon Christiaan Barnard at Groote ... Miniati, Douglas N.; Robbins, Robert C. (2002). "Heart transplantation: a thirty-year perspective: A Thirty-Year Perspective". ... Cooley, Denton A. (2011). "Recollections of the Early Years of Heart Transplantation and the Total Artificial Heart". ...
Nucleus transplantation experiments in mouse zygotes in the early 1980s confirmed that normal development requires the ... arguing that natural selection is operating on the role of epigenetic marks as machinery for homologous chromosome recognition ...
Somatic cell nuclear transplantation has become a focus of study in stem cell research. The aim of carrying out this procedure ... though questions remain on how homologous the two cell types truly are. Somatic cell nuclear transfer is a technique for ...
Clarkson K, Rosenfeld B, Fair J, Klein A, Bell W (Dec 1991). "Factor XI deficiency acquired by liver transplantation". Annals ... a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein". Biochemistry. 25 (9 ... a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein". Biochemistry. 25 (9 ...
Then, homologous recombination occurs naturally within some cells, replacing the gene of interest with the designed transgene. ... adapting animal organs for transplantation into humans, and the production of pharmaceutical products such as insulin, growth ...
What is homologous transplantation? Meaning of homologous transplantation medical term. What does homologous transplantation ... Looking for online definition of homologous transplantation in the Medical Dictionary? homologous transplantation explanation ... Homologous transplantation , definition of homologous transplantation by Medical dictionary https://medical-dictionary. ... a href=https://medical-dictionary.thefreedictionary.com/homologous+transplantation,homologous transplantation,/a,. *Facebook ...
Results of search for su:{Transplantation, Homologous.} Refine your search. *Availability * Limit to currently available ... Human fetal tissue transplantation research : report of the Advisory Committee to the Director, National Institutes of Health, ... Report of the Human Fetal Tissue Transplantation Research Panel, December 1988 / consultants to the Advisory Committee to the ... by Human Fetal Tissue Transplantation Research Panel , Advisory Committee to the Director, National Institutes of Health ...
Homologous lung transplantation (experiences in the dog). Faber, P; Kenwell, J M; Beattie, E J Jr. ... Modifications du sarcome J après transplantation sur des souris hybrides (Changes in Sarcoma J after transplantation in hybrid ... Adoptive transfer of transplantation immunity by means of blood-borne cells. Billingham, R E; Silvers, W K; Wilson, D B ... Studies on the rejection of the transplanted homologous dog liver. Starzl, T E; Kaupp, H A; Breck, D R; More ...
Keywords: Paralysis, obstetric; Brachial plexus neuropathy; Tendon transfer; Transplantation; Homologous; Shoulder; Arthroscopy ... It is then stretched and reinforced with a homologous tendon from a tissue bank (Fig. 5), which is trimmed to have the same ... Obstetric paralysis: anterior arthroscopic release of the shoulder and transfer of the latissimus dorsi using a homologous ... Tendon transplantation in obstetrical paralysis. Am J Surg. 1934;25:122-5. [ Links ] ...
Hepatology (Baltimore, Md.). A panel of recognized experts in liver transplantation pathology, hepatology, and surgery was ... Homologous. *Humans. *Liver Transplantation. *Liver Transplantation: immunology. *Liver Transplantation: pathology. * ... A panel of recognized experts in liver transplantation pathology, hepatology, and surgery was convened for the purpose of ...
Pulmonary Artery / transplantation* * Sensitivity and Specificity * Tissue Transplantation * Transplantation, Homologous / ...
Genetic and Rare Diseases Information Center resources: Homologous Wasting Disease U.S. FDA Resources ... Allogeneic stem cell transplantation is the treatment of choice for a growing number of malignant and non-malignant indications ... It was also used in stem-cell transplantation (SCT) for the same purposes (e.g. for generation of tolerance and rejection ... The aim of allogeneic non-myeloablative stem cell transplantation (NST) is to induce host-to-graft tolerance with fast and ...
Haematopoietic stem cell transplantation has been proposed as treatment for mitochondrial neurogastrointestinal ... Seven patients (29%) who were engrafted and living more than 2 years after transplantation, showed improvement of body mass ... Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy Brain. 2015 Oct; ... Haematopoietic stem cell transplantation has been proposed as treatment for mitochondrial neurogastrointestinal ...
Genetic and Rare Diseases Information Center resources: Homologous Wasting Disease U.S. FDA Resources ... Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation (HSCT). This ... Patients must be between 1 and 60 years of age and be a candidate for myeloablative donor stem cell transplantation ... The effect of etanercept on plasma cytokine levels after Hematopoietic Stem Cell Transplantation (HSCT) was analyzed. Tumor ...
Genetic and Rare Diseases Information Center resources: Homologous Wasting Disease U.S. FDA Resources ... Cannabidiol for Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation. The safety and scientific ... As such, it may reduce the incidence and severity of GVHD after allogeneic stem cell transplantation. ... Safety and Efficacy of Oral Cannabidiol for GVHD Prophylaxis in Allogeneic Stem Cell Transplantation. ...
Has received previous allogenic bone-marrow transplant or double umbilical cord transplantation (dUCBT). ... are positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD). ... A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm ... Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation ( ...
HHSCT: homologous hematopoietic stem cell transplantation; GI: gastrointestinal; CMV: cytomegalovirus.. 2.2. Methods. In each ... which lasts for about 20 days after transplantation, can induce apoptosis [11]. After allogeneic transplantation, ... In definition, GVHD occurs within 100 days of transplantation [5]. Primary target organs are the skin, liver, and GI tract, and ... It is essential to balance the risks of GVHD and infections to improve treatment efficacy after allogeneic transplantation. ...
Keywords : Knee; Transplantation homologous; Anterior cruciate ligament; Tendon injuries. · abstract in Portuguese · text in ...
Transplantation, Homologous. Treatment Failure. From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine ... Heart Transplantation / adverse effects*. Humans. Infant. Kaplan-Meier Estimate. Reoperation. Retrospective Studies. Risk ...
... associated with allogeneic bone marrow transplantation (BMT) is critical for clinical management. However, studies methodically ... Transplantation, Homologous. Comments/Corrections. From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine ... Bone Marrow Transplantation*. Colon / pathology*. Female. Graft vs Host Disease / pathology*. Humans. Male. Middle Aged. ... Without any transplantation and immunosupresion.. With GI symptoms like diarrhea, guaiac positive stool.. Negative control ...
Transplantation homologous. Resumé en anglais. Valve substitutes are highly important in account of their frequent use and ... L-Hydro treated homologous pulmonary graft vs. pulmonary homograft fresco: an experimental, comparative study ...
Transplantation autologus. Transplantation homologous. Resumo em inglês. Introduction: In the present study, biomarkers were ... Two hundred and sixteen (73%) were submitted to autologous transplantations and 80 (27.0%) to allogeneic ones. Out of the 80 ... The independent variables associated with death were: allogeneic transplantation, Gram-negative infection, DHL >= 390UI/L at ... Hematopoietic stem cell transplantation. Interleukin-6. Neutropenia/etiology. Procalcitonin. ...
Liu J, Sheha H, Fu Y, Liang L, Tseng SC (2010) Update on amniotic membrane transplantation. Expert Rev Ophthalmol 5:645-661. ... In this study, we describe the use of banked homologous AM as a dural substitute for the repair of spinal dysraphism in ... Sridhar MS, Bansal AK, Sangwan VS, Rao GN (2000) Amniotic membrane transplantation in acute chemical and thermal injury. Am J ... Myelomeningocele repair Amniotic membrane Spina bifida treatment Myelomeningocele surgery Spinal cord tethering Homologous ...
Autologous and homologous transplantation of bovine spermatogonial stem cells. Reproduction, 126: 765-774. ... To date, successful germ cell transplantations have been reported in several livestock species, e.g. transplantation of SSC in ... Transplantation of ovarian tissue and germ cells (e.g. PGC or spermatogonial stem cells [SSC]) are emerging technologies with ... Germ cell transplantation research has been developed as a unique approach for the study of gametogenesis and germ line ...
Immunity to homologous grafted skin. III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to ... Successful islet/abdominal testis transplantation does not require Leydig cells. Transplantation 50: 649-653. ... intratesticular islet transplantation by itself only slightly prolongs allograft survival compared with islet transplantation ... Skin transplantation. Skin donors were wt C3H/HeJ (third party) or BALB/c mice. Recipient mice were wt C57BL/6 mice that were ...
Transplantation, Homologous. 1. 2016. 4785. 0.090. Why? Internet. 1. 2019. 2957. 0.090. Why? ...
Graft vs Host Disease, Peripheral Blood Stem Cell Transplantation, Transplantation, Homologous. Thank you ... History of autologous or allogeneic transplantation. - Evidence of HIV seropositivity. - Evidence of active infection. - ... Undergoing myeloablative peripheral blood stem cell transplantation. - Have an HLA matched-related or matched-unrelated donor ( ... Meeting institutional standard criteria for allogeneic PBSC transplantation. Exclusion Criteria:. - Patient has >Grade 2 ...
Homologous meniscus transplantation. Experimental and clinical results. Int Orthop. 1989; 13(1): 1-11. ... Cruz-Lopez F, Olivos-Meza A, Llano-Rodr guez LT, Ibarra C. Arthroscopic meniscal transplantation technique. J Sports Med Doping ... Midterm and long-term results of medial versus lateral meniscal allograft transplantation: a meta-analysis. Am J Sports Med. ... Rosso F, Bisicchia S, Bonasia DE, Amendola A. Meniscal allograft transplantation: a systematic review. Am J Sports Med. 2015; ...
Experimental whole-organ transplantation of the liver and of the spleen. Moore, F. D.; Wheeler, H. B.; Demissianos, H. V.; More ... THE EFFECT OF FREEZING ON THE ACCEPTANCE OR REJECTION OF AUTOLOGOUS AND HOMOLOGOUS SKIN TRANSPLANTS. Ashley, Charles A.; ... TRANSPLANTATION IMMUNITY PRODUCED BY HOMOGRAFTS IN THE ANTERIOR OCULAR CHAMBER-A SO-CALLED PRIVILEGED SITE. CONNELLY, DAVID M. ... Renal transplantation in azotemic dogs. Mannick, J. A.; Powers, J. H.; Mithoefer, J.; More ...
Acetabulum,Bone Plates,Bone Transplantation,Femur Head,Femur Head Necrosis,Fracture Fixation,Fractures ...
... - Harald Reinhard, Thomas Klingebiel, Peter Lang, Peter Bader, Dietrich ... Transplantation, Homologous. Join CureHunter, for free Research Interface BASIC access!. Take advantage of free CureHunter ... Stem cell transplantation for polycythemia vera.. Abstract. Polycythemia vera (PV) is a rare disease in children. A 9-year-old ... A single dose of donor T-lymphocytes was given at month 3. One year after transplantation, chimerism was complete. The patient ...
Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first ... Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first ... for transplantations performed between 2003 and 2006 (p = 0.02), despite increasing recipient age. In a multivariate analysis, ... study was to analyze results and to determine factors affecting outcome of HLA-matched hematopoetic stem cells transplantation ...
Mechanism and regulation of human non-homologous DNA end-joining. Nat Rev Mol Cell Biol 2003;4:712-720. ... Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 1999;340:508-516. ... Boost transplantation.. Twelve patients (12%) received 1 or 2 boosts 2.5 to 15 years after the first HSCT (Table S2) In 7 ... Bone marrow transplantation in congenital immunodeficiency diseases. Bone Marrow Transplant 1998;21 suppl 2:S21-S23. ...
  • The tissue may be autologous, heterologous, or homologous. (bioportfolio.com)
  • Our purpose was to study retinal pigment epithelium (RPE) wound healing in patients with age-related macular degeneration (AMD).Abrasive debridement of nasal RPE was performed with a metal cannula during pars plana vitrectomy for foveal choroidal neovascularization (CNV) membrane excision combined with simultaneous autologous RPE transplantation. (stanford.edu)
  • The objective of this study was to evaluate the behavior of tibia autologous grafts compared with freeze-dried homologous bone in maxillary sinus floor lifting. (scielo.org.co)
  • Bone marrow is the traditional source of stem cells for both autologous and homologous transplants. (medscape.com)
  • Pilot studies of autologous stem cell transplantation using peripheral blood have demonstrated rapid engraftment with this technique. (medscape.com)
  • Homologous or autologous tissue represents one possible source of Schwann cells for transplantation into patients with demyelinating disease. (jneurosci.org)
  • To study the mechanism of the lipoprotein changes on bone marrow transplantation, the in vivo turnover of autologous serum (β)VLDL was studied. (ahajournals.org)
  • Autologous and allogeneic haematopoietic stem cell (HSC) transplantation has been performed in patients with various malignant and non-malignant haematological disorders for more than 50 years. (who.int)
  • Ex vivo gene modification of HSCs for autologous transplantation opens up new therapeutic avenues for genetic and infectious diseases. (who.int)
  • 1] cel s, but since the treatment targets all rapidly dividing cel s in the Following transplantation of autologous gene-modified HSCs body, it also depletes the HSC compartment in the bone marrow. (who.int)
  • Autologous transplantation of the patient's own of vision loss - a new era of modern medicine has been entered HSCs, which have been gene-modified to correct for the underlying into where one can imagine the use of `single-treatment cures' for genetic cause of the disease, would thus be the preferred form of life-threatening and previously incurable diseases. (who.int)
  • The present review aims at describing principal features of the aforementioned gynaecological complications of HSCT, and to define, on the basis of current international literature, a specific protocol for the prevention, diagnosis, management and follow-up of gynaecological complications of both autologous and heterologous transplantation, before and after the procedure. (springer.com)
  • Otherwise, in the second part, which represents the aim of the present paper, we define, on the basis of current international literature, a specific protocol for the prevention, diagnosis, management and follow-up of gynaecological complications of both autologous and heterologous transplantation, before and after the procedure. (springer.com)
  • This is a clinical trial to see if the addition of etanercept to standard preventative medicines helps in preventing two major complications of hematopoietic stem cell transplantation (HSCT): decrease the rate of acute graft-vs-host disease (GVHD) and the risk of death. (clinicaltrials.gov)
  • In order to determine whether etanercept, given prophylactically along with a standard Graft Versus Host Disease (GVHD) prevention regimen, will decrease the 100-day mortality and the rate of acute GVHD after allogeneic hematopoietic stem cell transplantation(HSCT), the incidence of grades 2-4 and grades 3-4 GVHD were calculated. (clinicaltrials.gov)
  • The effect of etanercept on plasma cytokine levels after Hematopoietic Stem Cell Transplantation (HSCT) was analyzed. (clinicaltrials.gov)
  • This is a clinical trial to see if the addition of etanercept helps in preventing two major complications of hematopoietic stem cell transplantation (HSCT). (clinicaltrials.gov)
  • Graft versus host disease (GVHD) is one of the major causes of death in patients undergoing allogeneic hematopoietic cell transplantation. (clinicaltrials.gov)
  • Of 1231 patients who underwent allogeneic hematopoietic stem cell transplantation between January 2005 and December 2014, 186 of whom underwent colonoscopy and biopsy and had no cytomegalovirus infection. (hindawi.com)
  • However, because GVHD is frequently accompanied by various infections that developed after hematopoietic stem cell transplantation as well as by disorders induced by nonimmunological mechanisms, it is difficult to identify GVHD based solely on clinical symptoms [ 2 ]. (hindawi.com)
  • In this study, we therefore retrospectively investigated the incidence and endoscopic features of GI GVHD that had occurred within 100 days of hematopoietic stem cell transplantation and analyzed the association between the endoscopic features and histopathological GVHD. (hindawi.com)
  • Of 1231 patients who underwent allogeneic hematopoietic stem cell transplantation between January 2005 and December 2014, 523 developed GI symptoms indicative of GVHD such as diarrhea and poor appetite and 222 subsequently underwent colonoscopy. (hindawi.com)
  • Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first complete remission treated in Eastern European centers. (curehunter.com)
  • Since the early beginnings, in the 1950s, hematopoietic stem cell transplantation (HSCT) has become an established curative treatment for an increasing number of patients with life-threatening hematological, oncological, hereditary, and immunological diseases. (frontiersin.org)
  • Harnessing embryonic stem (ES) cells as a source of HSCs would facilitate genetic modification of stem cell populations precisely by homologous recombination, enable basic investigation into genetic and epigenetic influences on hematopoietic cell function, and empower preclinical models for gene and cellular therapy. (aacrjournals.org)
  • HLA-haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide is associated with low rates of severe graft-versus-host disease and nonrelapse mortality and does not require graft manipulation or storage, which results in a low graft acquisition cost. (bioportfolio.com)
  • Several large, registry-based retrospective studies have confirmed the efficacy of HLA-haploidentical hematopoietic stem cell transplantation with posttransplant cyclophosphamide, achieving results comparable to those of HLA-matched hematopoietic stem cell transplantation. (bioportfolio.com)
  • Pediatric unmanipulated haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide and reduced intensity, TBI-free conditioning regimens in salvage transplantations. (bioportfolio.com)
  • Haploidentical hematopoietic stem cell transplantation with post-transplant high-dose cyclophosphamide in high-risk children: A single-center study. (bioportfolio.com)
  • Many patients suffering various malignant and non-malignant diseases need hematopoietic stem cell transplantation from a healthy person. (bioportfolio.com)
  • Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms. (bioportfolio.com)
  • Palmer JM, Rajasekaran K, Thakar MS, Malarkannan S. Clinical Relevance of Natural Killer Cells Following Hematopoietic Stem Cell Transplantation. (jcancer.org)
  • Natural killer (NK) cells are one of the first cells to recover following allogeneic hematopoietic stem cell transplantation (HSCT), and are believed to play an important role in facilitating engraftment or preventing post-transplant infection and tumor recurrence. (jcancer.org)
  • Since than much progress has been made and nowadays Hematopoietic Stem Cell Transplantation (HSCT) is considered the most effective treatment of numerous severe haematological diseases. (springer.com)
  • Medawar's legacy to cellular immunology and clinical transplantation: a commentary on Billingham, Brent and Medawar (1956) 'Quantitative studies on tissue transplantation immunity. (royalsocietypublishing.org)
  • This work influenced both immunology researchers and clinicians and helped to lay the foundations for successful transplantation programmes. (royalsocietypublishing.org)
  • The goal of this study was to analyze results and to determine factors affecting outcome of HLA-matched hematopoetic stem cells transplantation (MRD-HSCT) for patients with acute leukemia transplanted in first complete remission in Eastern European countries. (curehunter.com)
  • HSCs) for therapeutic applications has been in development for Haematopoietic stem cell transplantation (HSCT) is a global y over 30 years, and two such treatments were recently granted accepted practice for the treatment of malignant and non-malignant market authorisation by the European Medicines Agency. (who.int)
  • Allogeneic HSCT, i.e. transplantation of HSCs harvested in the annual number and volume of blood transfusions. (who.int)
  • The nonworking heterotopic heart transplantation model has been used extensively for the study of rejection and coronary endothelial function in different species. (hku.hk)
  • The effect of left ventricular loading in a working heart transplantation model, which may be associated with different coronary flow patterns and local nitric oxide release, on the development of coronary endothelial dysfunction and intimal hyperplasia, is unknown. (hku.hk)
  • 100 days after orthotopic heart transplantation. (medscape.com)
  • Shumway and Kantrowitz were poised for clinical application of heart transplantation when Christiaan Barnard electrified the world with the first human heart transplantation in Cape Town, South Africa, on December 3, 1967 (Figure 1A). (medscape.com)
  • Three days later, Adrian Kantrowitz performed the world's first infant heart transplantation on an 18-day-old infant with Ebstein anomaly using the heart of an anencephalic infant. (medscape.com)
  • Barnard performed the third heart transplantation on January 2, 1968, resulting in the first long-term survivor (18 months). (medscape.com)
  • Shumway performed the fourth heart transplantation 4 days later (Figure 1B). (medscape.com)
  • Anatomy of heart transplantation. (medscape.com)
  • A , Orthotopic heart transplantation. (medscape.com)
  • B , Heterotopic heart transplantation. (medscape.com)
  • Although heterotopic heart transplantation had a long history in the experimental laboratory, it was first used clinically in 1974 by Losman and Barnard. (medscape.com)
  • Thymoglobuline is a polyclonal rabbit antiserum specific for human T cells used in organ transplantation for induction of tolerance and rejection prevention and treatment. (clinicaltrials.gov)
  • A major barrier to progress in pig-to-primate organ transplantation is the presence of terminal α-1,3-galactosyl (Gal) epitopes on the surface of pig cells. (sciencemag.org)
  • Although renal transplantation had been performed sporadically during the first half of this century ( 2 ) ( 3 ), planned programs for human organ transplantation started only in the late 1940's. (nobelprize.org)
  • The full story of successful organ transplantation in man weaves together three separate pathways: the study of renal disease, skin grafting in twins, and surgical determination. (nobelprize.org)
  • Experimental whole-organ transplantation of the liver and of the spleen. (linkos.cz)
  • Transplantation, Heterotopic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (umassmed.edu)
  • H-Y is a transplantation antigen that can lead to rejection of male organ and bone marrow grafts by female recipients, even if the donor and recipient match at the major histocompatibility locus of humans, the HLA (human leukocyte antigen) locus. (sciencemag.org)
  • A targeted neuroglial reporter line generated by homologous recombination in human embryonic stem cells. (ca.gov)
  • The present work reports an hESC reporter line generated by homologous recombination targeting a neural lineage-specific gene, which can be differentiated and sorted to obtain pure neural progenitor populations. (ca.gov)
  • Despite the immune regulation, intratesticular islet allografts all were rejected within 42 days after transplantation although they survived longer than renal subcapsular islet allografts. (jimmunol.org)
  • Homologous and heterologous immune sera may inactivate leukemic cells in vitro . (aacrjournals.org)
  • Heterologous transplantation of leukemic cells can be accomplished by previous radiation of the foreign host, but not by inoculation into the anterior chamber of the eye. (aacrjournals.org)
  • The resultant fetuses, embryos or offspring are especially useful for the expression of desired heterologous DNAs, and may be used as a source of cells or tissue for transplantation therapy for the treatment of diseases such as Parkinson's disease. (freepatentsonline.com)
  • In contrast, actively immune mice infected with different Borrelia species ( B. burgdorferi sensu lato, B. burgdorferi sensu stricto cN40, Borrelia afzelii PKo, and Borrelia garinii PBi) and then treated with an antibiotic were resistant to challenge with cultured homologous but not heterologous spirochetes. (asm.org)
  • Later on, with the concept of using irradiation for therapeutic elimination of leukemia, the use of conditioning regimens for successful transplantation was introduced into clinic. (frontiersin.org)
  • We conducted a retrospective analysis of all known patients suffering from mitochondrial neurogastrointestinal encephalomyopathy who underwent allogeneic haematopoietic stem cell transplantation between 2005 and 2011. (nih.gov)
  • Allogeneic stem cell transplantation is the treatment of choice for a growing number of malignant and non-malignant indications. (clinicaltrials.gov)
  • The aim of allogeneic non-myeloablative stem cell transplantation (NST) is to induce host-to-graft tolerance with fast and durable engraftment of donor stem cells, by means of conditioning, which is well-tolerated by patients. (clinicaltrials.gov)
  • It was also used in stem-cell transplantation (SCT) for the same purposes (e.g. for generation of tolerance and rejection preclusion) as well as a treatment for graft-versus-host disease (GVHD). (clinicaltrials.gov)
  • 24 24 Stem Cell Transplantation Unit, Internal Medicine Department, Ribeirao Preto School of Medicine, Sao Paulo University, Brazil. (nih.gov)
  • Haematopoietic stem cell transplantation has been proposed as treatment for mitochondrial neurogastrointestinal encephalomyopathy, a rare fatal autosomal recessive disease due to TYMP mutations that result in thymidine phosphorylase deficiency. (nih.gov)
  • Twenty-four patients, 11 males and 13 females, median age 25 years (range 10-41 years) treated with haematopoietic stem cell transplantation from related (n = 9) or unrelated donors (n = 15) in 15 institutions worldwide were analysed for outcome and its associated factors. (nih.gov)
  • As such, it may reduce the incidence and severity of GVHD after allogeneic stem cell transplantation. (clinicaltrials.gov)
  • Patients undergoing allogeneic stem cell transplantation. (clinicaltrials.gov)
  • To evaluate the maximum tolerated dose (MTD) of bortezomib in combination with tacrolimus and sirolimus as GVHD prophylaxis in patients undergoing myeloablative allogeneic peripheral blood stem cell transplantation. (knowcancer.com)
  • Stem cell transplantation for polycythemia vera. (curehunter.com)
  • At the age of 12 years, HLA-matched unrelated stem cell transplantation including T-cell depletion was done. (curehunter.com)
  • Now, treatment of a number of diseases is possible through stem cell transplantation. (medscape.com)
  • Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. (nih.gov)
  • How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide. (bioportfolio.com)
  • Unmanipulated haploidentical stem cell transplantation (haploSCT) with post-transplant cyclophosphamide is an option for patients with advanced hematologic malignancies. (bioportfolio.com)
  • Primary objective of this open label, two-arm, multicenter, multinational, randomized trial is to compare anti-leukemic activity of allogeneic stem cell transplantation for patients with a. (bioportfolio.com)
  • Human renal transplantation III. (medscape.com)
  • The Prevention of Acute Tubular Necrosis in Renal Transplantation by Chronic Salt Loading of the Recipient. (infertile.com)
  • Renal Transplantation Between Adults and Children. (infertile.com)
  • At that time clinicians in Paris, London, Edinburgh and Boston began renal transplantation in unmodified human recipients in spite of the warnings and pessimistic predictions of many scientists and experienced clinicians. (nobelprize.org)
  • The medical and surgical services, along with the Department of Pathology under Dr. Gustave J. Dammin, led the way and ultimately renal transplantation involved most of the hospital in some way or other. (nobelprize.org)
  • Kidney transplantation between seven pairs of identical twins. (medscape.com)
  • Kidney Transplantation in Inbred Rats. (infertile.com)
  • The percentage of the donors against which the recipient reacts is used as a predictor of the likelihood of a positive cross-match that would prevent transplantation. (medscape.com)
  • OBJECTIVE: To compare the frequency and type of neurological complications after bone marrow transplantation (BMT) with an HLA identical unrelated donor or a mismatched related donor (alternative donors) to the neurological complications after matched sibling BMT for standard and high risk leukaemia or myelodysplastic syndromes. (eur.nl)
  • A panel of recognized experts in liver transplantation pathology, hepatology, and surgery was convened for the purpose of developing a consensus document for the grading of acute liver allograft rejection that is scientifically correct, simple, and reproducible and clinically useful. (mendeley.com)
  • Thus, transplantation tolerance requires both costimulatory blockade, which suppresses acute allograft rejection, and a favorable balance between memory and regulatory T cells that could favorably prevent late allograft failure. (jimmunol.org)
  • The objective was to describe the clinical evolution of patients with pain associated with postmenisectomy syndrome, who underwent meniscal allograft transplantation (MAT), with bony blocks via arthroscopy, with follow-up to one year. (medigraphic.com)
  • Rosso F, Bisicchia S, Bonasia DE, Amendola A. Meniscal allograft transplantation: a systematic review. (medigraphic.com)
  • Prospective evaluation of allograft meniscus transplantation: a minimum 2-year follow-up. (medigraphic.com)
  • Midterm and long-term results of medial versus lateral meniscal allograft transplantation: a meta-analysis. (medigraphic.com)
  • International meniscus reconstruction experts forum (IMREF) 2015 consensus statement on the practice of meniscal allograft transplantation. (medigraphic.com)
  • The use of contralateral knee magnetic resonance imaging to predict meniscal size during meniscal allograft transplantation. (medigraphic.com)
  • Long-term clinical outcome of open meniscal allograft transplantation. (medigraphic.com)
  • Hommen JP, Applegate GR, Del Pizzo W. Meniscus allograft transplantation: ten-year results of cryopreserved allografts. (medigraphic.com)
  • Current opinion in meniscal allograft transplantation. (scielo.org.za)
  • The cumulative incidence of NRM decreased from 22 +/- 2% for patients treated between 1990 and 2002 to 15 +/- 3% for transplantations performed between 2003 and 2006 (p = 0.02), despite increasing recipient age. (curehunter.com)
  • The present study should encourage the design of clinical trials aimed to test the efficacy of this strategy to offer new therapeutic opportunities to patients challenged by ischemia-reperfusion events not solely in heart, but also in other organs such as kidney or liver in transplantation surgeries. (frontiersin.org)
  • Cudkowicz G, Cosgrove GE (1961): Modified homologous disease following transplantation of parental bone marrow and recipient liver into irradiated FI mice. (springer.com)
  • Fine-needle aspiration biopsy (FNAB) is a routine diagnostic tool used for the monitoring of the graft during the first postoperative weeks after liver transplantation. (uni-regensburg.de)
  • Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? (elsevier.com)
  • Tacrolimus has proven to be a potent immunosuppressive agent in liver transplantation (LT). Its introduction has led to significantly less frequent and severe acute rejection. (elsevier.com)
  • Fingerprint Dive into the research topics of 'Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? (elsevier.com)
  • Liver Transplantation , 7 (7), 623-630. (elsevier.com)
  • Inseparable part of liver transplantation procedure, anesthesia, and perioperative care for the liver transplant recipient has made a remarkable progress during last decades, becoming a clinical specialty with well-defined goals, requirements, and approaches. (intechopen.com)
  • Welch, C.S.: A note on transplantation of the whole liver in dogs. (linkos.cz)
  • Liver transplantation for treatment of small hepatocellular carcionomas in patients with cirrhosis. (linkos.cz)
  • Recent Advances i Liver Transplantation. (linkos.cz)
  • National Institutes of Health Consensus Development Statement: Liver transplantation. (linkos.cz)
  • Homologous recombination 19. (coursehero.com)
  • Homologous Recombination Mediates Functional Recovery of Dysferlin Deficiency following AAV5 Gene Transfer. (nationwidechildrens.org)
  • In this study, we targeted Olig2, a basic helix-loop-helix transcription factor that plays an important role in motoneuron and oligodendrocyte development, in human embryonic stem cell (hESC) line BG01 by homologous recombination. (ca.gov)
  • One of the two defective rag2 alleles was repaired by homologous recombination to generate the ntESRag2 +/− line. (aacrjournals.org)
  • A study of the effects of drugs in prolonging survival of homologous renal transplants in dogs. (medscape.com)
  • Russian scientist Vladimir Demikhov performed pioneering transplantation experiments in the 1940s and 1950s, including canine heart and heart-lung transplants. (medscape.com)
  • BACKGROUND: Proper histomorphological interpretation of intestinal acute graft versus host disease (A-GVHD) associated with allogeneic bone marrow transplantation (BMT) is critical for clinical management. (biomedsearch.com)
  • Bronchiolitis obliterans organizing pneumonia and ulcerative colitis after allogeneic bone marrow transplantation. (ac.be)
  • en] A 37-year-old man with acute myeloblastic leukemia in first remission developed ulcerative colitis and bronchiolitis obliterans organizing pneumonia (BOOP) 7 months after bone marrow transplantation (BMT) from an HLA-matched brother who suffered from severe Crohn's disease. (ac.be)
  • We analyzed the clinical course and risk factors of 18 patients with poor engraftment after allogeneic bone marrow transplantation (BMT), defined as absolute neutrophil count below 0.1×10 9/1 28 days post-BMT. (hku.hk)
  • The influence of apoE gene dosage on serum lipid concentrations was determined by transplantation of homozygous apoE-deficient (apoE −/− ), heterozygous apoE-deficient (apoE +/− ), and wild-type (apoE +/+ ) bone marrow in homozygous apoE-deficient mice. (ahajournals.org)
  • Diminished DNA double-strand break repair in the Lig4 Y288C strain causes a progressive loss of haematopoietic stem cells and bone marrow cellularity during ageing, and severely impairs stem cell function in tissue culture and transplantation. (nature.com)
  • The observation was unexpected, as transplantation antigens are known to be inherited codominantly (Snell, 1953) and therefore parental marrow grafts should not be subject to immunological rejection mechanisms. (springer.com)
  • The viability of articular cartilage in fresh osteochondral allografts after clinical transplantation. (scielo.org.za)
  • Sixty days after transplantation, epicardial coronary arteries from working and nonworking allografts developed a comparable selective endothelial dysfunction of Gi-protein mediated relaxations. (hku.hk)
  • Clinical transplantation has become one of the preferred treatments for end-stage organ failure since the introduction of chronic immunosuppressive drugs in the mid-1980s. (sciencemag.org)
  • Partial restoration of the immune deficiency of rag2 −/− mice was achieved by transplantation of HSCs derived in vitro from the ntESrag2 +/− line. (aacrjournals.org)
  • 1931). "A genetic study of the transplantation of tumors arising in hybrid mice. (springer.com)
  • Some experiments on transplantation of cancer in Japanese mice. (springer.com)
  • Sera obtained from mice following infection with high and low doses of cultured B. burgdorferi sensu stricto, transplantation of infected tissue (host-adapted spirochetes), or tick-borne inoculation all showed protective activity in passive immunization assays. (asm.org)
  • Infection and disease were similar in mice infected with cultured spirochetes or by transplantation. (asm.org)
  • Mice infected with B. burgdorferi sensu stricto and then cured of infection with an antibiotic during early or late stages of infection were resistant to challenge with high doses of homologous cultured spirochetes for up to 1 year. (asm.org)
  • Similar results were achieved for actively immune mice challenged by transplantation and by passive immunization with sera from mice infected with each of the Borrelia species and then challenged with cultured spirochetes. (asm.org)
  • Arthritis and carditis in mice that had immunizing infections with B. afzelii and B. garinii and then challenged by transplantation with B. burgdorferi sensu stricto were equivalent in prevalence and severity to those in nonimmune recipient mice. (asm.org)
  • As determined with immunoblots against cultured B. burgdorferi lysate antigen, the antibody response in mice infected following inoculation with low doses of spirochetes is similar to that in mice infected with tick-borne spirochetes as well as that in mice infected with host-adapted spirochetes introduced by transplantation of infected tissue ( 9 , 15 , 27 , 38 , 43 ). (asm.org)
  • The sensitivity of haematopoietic stem cells to non-homologous end-joining deficiency is therefore a key determinant of their ability to maintain themselves against physiological stress over time and to withstand culture and transplantation. (nature.com)
  • Here we found that islet transplantation in the testis, an immunologically privileged site, generates much less memory CD8 + T cells but induces more Ag-specific CD4 + CD25 + regulatory T cells than in a conventional site. (jimmunol.org)
  • Evidence that intrathymic islet transplantation does not prevent diabetes or subsequent islet graft destruction in RT6-depleted, diabetes-resistant BioBreeding/Worcester rats. (umassmed.edu)
  • The baby died of acute cardiac failure shortly after the transplantation. (medscape.com)
  • Transplantation of Rat Kidneys with Acute Tubular Necrosis into Salt-loaded and Normal Recipients. (infertile.com)
  • Together with Rudolf Jaenisch's laboratory, ES cells were used to model therapeutic HSC transplantation to manage genetic immune deficiency by therapeutic cloning. (aacrjournals.org)
  • Major advances have been made over the last three decades with respect to gene modification of HSCs and transplantation strategies, ultimately culminating in the approval of two such therapies in Europe (Strimvelis for a rare primary immune deficiency, and LentiGlobin for beta-thalassaemia). (who.int)
  • Genetic factors control the transplantation of leukemic cells. (aacrjournals.org)
  • First Global Consultation on Regulatory Requirements for Human Cells and Tissues for Transplantation, Ottawa, 29 November to 1December 2004 : report. (who.int)
  • Resistance to homologous transplantation of leukemic cells may be overcome by inoculation of large doses of cells into very young animals. (aacrjournals.org)
  • These data support the conclusion that transplantation of human Schwann cells results in functional remyelination of a dorsal column lesion. (jneurosci.org)
  • In mammalian cells, Cas9-induced DSBs are repaired largely by non-homologous end joining (NHEJ) and partly by homology-directed repair (HDR) that includes gene conversion, microhomology-mediated end joining (MMEJ), and single strand annealing (SSA) [ 1 , 6 ]. (biomedcentral.com)
  • Here we report the first successful case of chromosome transplantation by replacement of an endogenous X chromosome carrying a mutation in the Hprt genewith a normal one in mouse embryonic stem cells (ESCs), correcting the genetic defect. (sigmaaldrich.com)
  • Embryonic stem (ES) cells may be a tissue/cell source for developing the therapeutic potential of neural transplantation. (google.com)
  • Five consecutive patients underwent the proposed surgical procedure, consisting of arthroscopic anterior joint release followed by transfer of the latissimus dorsi tendon (elongated and reinforced with a homologous tendon graft) to the posterosuperior portion of the greater tubercle, using a single deltopectoral approach. (scielo.br)
  • The latissimus dorsi tendon can be transferred to the posterosuperior portion of the greater tubercle through a single deltopectoral approach when elongated and reinforced with a homologous tendinous graft. (scielo.br)
  • Paternal Expression of a Novel Imprinted Gene, Peg12/Frat3, in the Mouse 7C Region Homologous to the Prader-Willi Syndrome Region Biochemical and Biophysical Research Communications. (jove.com)
  • The protein from the homologous gene on the X chromosome, SMCX, differs by two amino acid residues in the same region. (sciencemag.org)
  • 1932). "Genetic studies on the transplantation of tumors. (springer.com)
  • Further investigations in transplantation of tumors. (springer.com)
  • The autonomous growth of tumors was demonstrated by transplantation experiments in which tumors from one animal survived and grew for many years on secondary animal hosts. (thefreedictionary.com)
  • A colonial protochordate, Botryllus schlosseri , undergoes a natural transplantation reaction in the wild that results alternatively in colony fusion (chimera formation) or inflammatory rejection. (pnas.org)
  • However, it is unknown whether testicular immune privilege promotes transplantation tolerance. (jimmunol.org)
  • Graft-versus-host disease (GVHD) and graft rejection are major problems following intestinal transplantation (IT). (elsevier.com)
  • Van Thiel, David H. / NK activity during graft-versus-host disease and graft rejection in rats following intestinal semiallogenic and allogenic transplantation with or without mesenteric lymphadenectomy . (elsevier.com)
  • Early diagnosis and treatment are essential for graft-versus-host disease (GVHD), which is a serious complication that influences the prognosis of patients after allogeneic transplantation [ 1 ]. (hindawi.com)